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“The greatest enemy of knowledge is not ignorance, 
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ACCORD Action to Control Cardiovascular Risk in Diabetes 
AGE   Advanced glycation end-product
ARB  Angiotensin receptor blocker
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RCT  Randomized controlled trial
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TGF-β   Transforming growth factor-β
UAER   Urinary albumin excretion rate
UKPDS  UK Prospective Diabetes Study
VO2max    Maximal oxygen uptake
WESDR  Wisconsin Epidemiologic Study of Diabetic Retinopathy
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Type 1 diabetes is a chronic condition with risk of severe long-term complications 
(cardiovascular disease, diabetic nephropathy, neuropathy and retinopathy) that 
increase the risk of premature mortality, reduce quality of life and cause a huge 
economic burden to society. The main cause of death and inability in individuals 
with type 1 diabetes are cardiovascular events, and it has been shown that diabetic 
nephropathy is the main driver of the increased risk of cardiovascular morbidity 
and mortality. Diabetic retinopathy is the leading cause of vision loss and blindness 
in developed countries. Physical activity has been shown to improve the risk profile 
of individuals with type 1 diabetes. Consequently, previous cross-sectional data 
show that lower physical activity is associated with a higher degree of diabetic 
complications, but the causal relationship is unclear.
Aim 
The aim of this thesis is to assess how the total amount of leisure-time physical activity 
(LTPA) and its components of intensity, frequency and duration are associated 
with the development of diabetic nephropathy, cardiovascular outcomes, diabetic 
retinopathy and mortality in type 1 diabetes.
Subjects and methods
The study subjects of this thesis are participants in the ongoing nationwide, multi-
centre Finnish Diabetic Nephropathy (FinnDiane) Study. Currently, more than 5000 
individuals with type 1 diabetes have been recruited and thoroughly characterized 
from all over Finland. LTPA was assessed at baseline by a validated self-report 
questionnaire. The study design is prospective and observational.  
Results 
The intensity of LTPA was associated with the initiation and progression of diabetic 
nephropathy. Of the other LTPA components, frequency was also associated with 
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the progression of diabetic nephropathy. In contrast, the total amount or duration 
of LTPA was not associated with the development or progression of diabetic 
nephropathy. 
A larger amount of total LTPA and its components were associated with lower 
risk of incident CVD events. The association between LTPA frequency and incident 
CVD remained significant after adjustment for potential confounders. Also, LTPA 
intensity showed a borderline effect on the recurrence-free time of CVD events in 
individuals with a previous CVD event. 
LTPA and all its components were associated with lower risk of all-cause 
mortality after adjusting for several confounders. However, only the LTPA intensity 
was associated with cardiovascular death after adjusting for covariates. Also, total 
LTPA and frequency of LTPA were independently associated with lower risk of 
mortality in individuals with type 1 diabetes and chronic kidney disease. 
Frequent LTPA was associated with lower risk of severe diabetic retinopathy. 
The total amount or other components of LTPA (intensity or duration of a single 
session) were not associated with severe diabetic retinopathy, however.
Conclusions
Physical activity was associated with reduced risk of diabetic complications and 
mortality in individuals with type 1 diabetes. In addition, physical activity also seems 
to benefit those with diabetic complications – notably, diabetic nephropathy – and 




Tyypin 1 diabetes on krooninen sairaus, johon liittyy vakavia komplikaatioita (sydän- 
ja verisuonisairaus, munuaistauti eli nefropatia, hermostosairaus eli neuropatia 
ja silmän verkkokalvosairaus eli retinopatia). Nämä liitännäissairaudet lisäävät 
ennenaikaisen kuoleman vaaraa, heikentävät elämänlaatua ja lisäävät huomattavasti 
terveydenhuollon kustannuksia. Sydän- ja verisuonisairaudet ovat tärkein 
kuolleisuutta ja sairastavuutta lisäävä komplikaatio tyypin 1 diabeteksessa. On 
osoitettu, että diabeettinen nefropatia on tärkein tätä riskiä lisäävä tekijä. Diabeettinen 
retinopatia on keskeinen syy näön heikentymiselle ja sokeudelle kehittyneissä 
maissa.  Fyysisen aktiviteetin on osoitettu parantavan tyypin 1 diabetesta sairastavien 
potilaiden riskijakaumaa. Aiemmat poikkileikkaustutkimukset ovat osoittaneet, että 
vähäinen liikunta liittyy diabeteksen komplikaatioiden lisääntymiseen, mutta syy-
seuraussuhde on epäselvä. 
Tavoitteet
Tämän väitöskirjan tavoitteena on arvioida, miten vapaa-ajan liikunta 
(kokonaismäärä, suorituksen kesto, intensiteetti ja frekvenssi) vaikuttaa 
komplikaatioiden kehittymiseen ja kuolleisuuteen tyypin 1 diabeteksessa. 
Tutkimusaineisto ja menetelmät
Väitöskirjan potilaat ovat osana jatkuvaa, koko Suomen kattavaa, FinnDiane–
monikeskustutkimusta. FinnDiane tutkimukseen on osallistunut jo yli 
5000 suomalaista tyypin 1 diabetesta sairastavaa potilasta. Tutkimuksessa 
potilaiden fyysinen aktiivisuus arvioitiin suomalaisiin olosuhteisiin validoidulla 
liikuntakyselylomakkeella. Tutkimus on luonteeltaan havainnoiva seurantatutkimus. 
Tulokset
Vapaa-ajan liikunnan vähäinen intensiteetti liittyi diabeettisen munuaissairauden 
aikaiseen ilmaantumiseen ja nopeaan etenemiseen. Lisäksi liikuntakertojen 
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määrä oli vastaavasti yhteydessä diabeettisen nefropatian ilmaantumiseen ja 
etenemiseen. Suurempi fyysisen aktiivisuuden määrä liittyi matalampaan sydän- 
ja verisuonikomplikaatioriskiin. Tuloksen tilastollinen merkitsevyys säilyi, vaikka 
mahdolliset sekoittavat tekijät huomioitiin. Fyysisen aktiivisuuden määrä oli 
yhteydessä kokonaiskuolleisuuteen myös munuaissairautta sairastavilla potilailla. 
Suurempi liikuntakertojen määrä liittyi pienempään riskiin sairastua diabeettiseen 
retinopatiaan. 
Johtopäätökset
Fyysinen aktiivisuus on yhteydessä vähäisempään riskiin sairastua diabeteksen 
komplikaatioihin ja kuolla ennenaikaisesti. Fyysinen aktiivisuus on hyödyllistä myös 
potilailla, joilla on jo liitännäissairauksia, kuten diabeettinen munuaissairaus. 
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1 INTRODUCTION 
Diabetes, a common chronic disease characterized by elevated blood glucose, 
constitutes a major global health problem. In 2014, the World Health Organization 
(WHO) estimated that 422 million adults are affected by diabetes. In addition, almost 
half the individuals living with diabetes are estimated to be undiagnosed (1). The 
most common forms of diabetes are type 1 and type 2 diabetes. Type 2 diabetes is 
characterized by insulin resistance and relative insulin deficiency. Type 1 diabetes, 
on the other hand, is characterised by a total loss of endogenous insulin production, 
and if left untreated, it leads to ketoacidosis and premature death. Therefore, until 
the discovery and availability of exogenous insulin in 1922, type 1 diabetes was a 
fatal disease with no cure. 
For reasons unknown, the incidence of type I diabetes is increasing worldwide 
in both low- and high-incidence populations (2). The onset of diabetes is shifting 
towards younger patients, although the incidence has increased in all age groups 
(3). Finland has the highest age-standardized incidence rate of type 1 diabetes in 
the world, with more than 60 per 100 000 per year in individuals below the age 
of 15 (4). Of the estimated half a million people affected by diabetes in Finland, a 
total of 50 000 have type 1 diabetes (5).
Although the quality of diabetes care and modes of insulin treatment have 
improved significantly over the years, type 1 diabetes is still associated with severe 
long-term complications that increase the risk of premature death and disability. 
These complications include microvascular complications such as diabetic 
nephropathy, diabetic retinopathy and diabetic neuropathy, as well as cardiovascular 
complications such as coronary artery disease, myocardial infarction, stroke and 
peripheral vascular disease. Cardiovascular disease (CVD) is the most common cause 
of death and disability among individuals with type 1 diabetes. Diabetic nephropathy 
(DN) accounts for a large extent of the increase in cardiovascular morbidity and 
mortality in these patients (6). It is of note that an elevated concentration of glucose in 
the circulation is needed (a prerequisite) for the development of these complications, 
although there are many other modifiable risk factors involved. Therefore, the 
treatment strategy for type 1 diabetes includes a multifactorial approach targeting 
all modifiable risk factors and not only optimizing the glycaemic control.
Physical activity has been shown to provide multiple significant health benefits 
in the general population and in individuals with type 2 diabetes (7). Importantly, 
physical activity has been instrumental in the primary and secondary prevention 
of type 2 diabetes and has been shown to reduce the risk of CVD and mortality 
in exposed individuals (7-10). In addition, it has been shown to improve several 
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vascular risk factors implicated in the pathogenesis of diabetic complications. For 
example, physical activity improves glucose and lipid control and insulin resistance 
and reduces body weight and blood pressure (7). 
However, there are surprisingly limited prospective data evaluating the causal 
effects of physical activity on the development of diabetic complications in type 1 
diabetes. No previous prospective studies have assessed the association of physical 
activity and the progression of diabetic nephropathy. In fact, physical activity 
guidelines for individuals with type 1 diabetes rely largely on information obtained 
from studies in type 2 diabetes or the general population (11). It is obvious that 
there is an urgent demand for evidence regarding which type of physical activity is 
most beneficial in terms of intensity, duration, volume and type for individuals with 
type 1 diabetes. Therefore, in this thesis, the aim is to evaluate how leisure-time 
physical activity and its components (intensity, frequency, volume and duration) are 
associated with the development of diabetic complications and premature mortality 
in individuals with type 1 diabetes.
16
2 REVIEW OF THE LITERATURE
2.1 Diabetes Mellitus 
2.1.1 Definition
Diabetes mellitus (DM) is a group of metabolic disorders characterized by chronically 
elevated blood glucose concentration due to defects in insulin secretion, insulin 
action or a combination of these two, leading to disturbed carbohydrate, fat and 
protein metabolism. The condition is associated with both serious acute and 
long-term complications affecting the quality of life and the life expectancy of the 
individual with DM. (12)
2.1.2 Classification of diabetes 
Based on their pathogenesis, the majority of cases with DM can be divided into two 
major classes, namely type 1 and type 2 diabetes (12). Type 1 diabetes, previously 
referred to as insulin-dependent diabetes or juvenile-onset diabetes, is characterized 
by autoimmune-mediated B-cell destruction in the pancreatic islets, leading to a 
loss of insulin secretion (12, 13). Type 2 diabetes, previously referred to as non-
insulin-dependent diabetes, is often linked to obesity with subsequent resistance 
to the insulin action in the target tissues and/or lack of insulin secretion as the 
disease progresses. However, because of disease heterogeneity and substantial 
overlap between the two major DM conditions, labelling a particular diabetes type 
is sometimes challenging (14).
There are also other forms of diabetes. Gestational diabetes is characterised 
by insulin resistance and hyperglycaemia discovered during pregnancy. This 
hyperglycaemia usually improves or disappears after labour. However, women with 
gestational diabetes have an increased risk of developing type 2 diabetes during 
follow-up. (15) While type 1 and type 2 diabetes are complex genetic disorders 
(caused by many genes), there are also rare monogenetic forms of diabetes, such 
as the various types of MODY (Maturity Onset Diabetes of the Young), of which 
MODY 3 is most common in Finland (16). There are also other rare monogenic 
conditions that cause diabetes. Notably, diabetes may also occur due to loss or 
damage of the pancreatic tissue caused by surgery, cancer, trauma or pancreatitis. 
Moreover, some drugs, e.g. glucocorticoids, have been shown to influence the glucose 
metabolism (17). Recently, a proposal for a new classification of diabetes based 
on the individual patient characteristics at diagnosis was introduced (18). These 
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characteristics include age at diagnosis, BMI, HbA1c, glutamate decarboxylase (GAD) 
antibodies and the homeostatic model assessment (HOMA) 2 estimates of β-cell 
function and insulin resistance. Time will tell whether this novel classification will 
gain broader implementation.
2.1.3 Diagnostic criteria
A diabetes diagnosis is based on measurements of glycated haemoglobin, fasting 
plasma glucose or plasma glucose after an oral glucose tolerance test. If an individual 
presents with the classic symptoms of diabetes (weight loss, polyuria, polydipsia 
and/or polyphagia) or a hyperglycaemic crisis, the diagnosis can be made based on 
a single plasma glucose measurement. However, the diagnosis must be confirmed 
with a repeated diagnostic measurement on a different day for an asymptomatic 
individual. The WHO’s (World Health Organization) diagnostic criteria for diabetes 
are a fasting plasma glucose level of ≥7.0 mmol/l (126 mg/dl), plasma glucose 
≥11.1 mmol/l (200 mg/dl) two hours after a 75 g oral glucose load, symptoms 
of hyperglycaemia, and a random plasma glucose concentration of ≥11.1 mmol/l 
(200 mg/dl) (19). The ADA (American Diabetes Association) has included a glycated 
haemoglobin of 48 mmol/mol (6.5%) or higher in their guidelines for a diagnosis 
of diabetes (14). 
2.1.4 Type 1 Diabetes – Epidemiology and Pathogenesis 
Type 1 diabetes accounts for 5–10% of diabetes cases. The incidence of type 1 diabetes 
is rapidly growing worldwide, indicating that lifestyle/environmental factors in 
genetically susceptible individuals play an important role for the onset of the disease 
(3). The geographical variation in the incidence of type 1 diabetes is large, with 
incidence rates (in children under 15 years) varying from 0.1 per 100 000/year in 
parts of Venezuela and China to 22 per 100 000/year in Canada to over 60 per 100 
000/year in Finland, which has the highest incidence rate of type 1 diabetes in the 
world (3, 20, 21). The age at onset of type 1 diabetes has been shifting towards the 
younger age groups, and there is a slight male excess in the individuals diagnosed 
with type 1 diabetes, whereas other autoimmune diseases are more common in 
women (3). Although the incidence of type 1 diabetes is highest in children, it is of 
note that the diagnosis can be made at any age. 
Type 1 diabetes is an autoimmune disease characterised by gradual immune-
mediated B-cell destruction of the pancreatic islets of Langerhans, resulting in a 
life-long dependence on exogenous insulin. Activation of the immune system by 
environmental triggers leads to an inflammatory response in susceptible individuals. 
A chain of functional defects in the bone marrow and thymus, immune system, and 
β cells together contribute to the pathogenesis of type 1 diabetes. (13) Symptoms of 
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diabetes occur when 80–90% of the β cells have been destroyed due to a chronic 
inflammatory process affecting the islets (22, 23). Islet autoantibodies, e.g. insulin 
autoantibodies (IAA), GAD antibodies, islet cell antibodies (ICA), insulinoma-
associated antigen-2 (IA-2A) and zinc transporter 8 antibodies (ZnT8) are detectable 
in 90% of individuals recently diagnosed with type 1 diabetes (24, 25). These 
antibodies can be detected years or even decades before the clinical manifestation 
of the disease by sensitive radioimmunoassays. The number of autoantibodies 
detected increases the risk of type 1 diabetes cumulatively (26). The presence of 
two or more autoantibodies – referred to as the point of no return – increases the 
risk of developing type 1 diabetes during the next 10 years to 70% (27). 
So far, over 50 genetic loci have been found that affect the genetic predisposition 
to type 1 diabetes. The majority of the identified gene loci are thought to involve 
immune responses. (28) The human leukocyte antigen (HLA) locus accounts for 
half of the genetic susceptibility to the disease (29). Of the many HLA types, the 
HLA class II shows the strongest association with type 1 diabetes. Also, genes that 
protect against type 1 diabetes have been identified (30). Many of these genetic 
markers are common in the Finnish population. However, only a relatively small 
proportion of individuals with risk alleles finally develop clinical disease (31). 
It is obvious that the rapidly increasing incidence rate of type 1 diabetes cannot 
be explained by changes in the genetic pool. Interestingly, immigrants with different 
ethnic backgrounds from low-incidence risk regions seem to be at higher incidence 
risk among the population in the new area (32). Further, the incidence rise in 
childhood disease manifestation is associated with weaker contributions from high-
risk HLA haplotypes (33). Therefore, an environmental/lifestyle influence is clear 
yet poorly understood. Various environmental factors including certain viruses, 
toxins and dietary factors may contribute, and hypotheses such as the “accelerator 
hypothesis” and the “hygiene hypothesis” have been suggested to explain the rapid 
increase in the type 1 diabetes incidence rate (34–36). 
2.1.5 Type 1 Diabetes – Treatment 
Before the milestone in the history of diabetes – the discovery of exogenous insulin 
in 1921 – diabetes was a fatal disease (37). Animal-derived insulin was the first 
insulin to be administered to humans, followed by human insulin and, further, 
by insulin analogues. After being diagnosed with type 1 diabetes, a patient can 
require minimal exogenous insulin for a time due to a partial recovery of β-cell 
function, a phenomenon called the “honeymoon period”. Interestingly, 30–80% 
of individuals with type 1 diabetes preserve small amounts of residual endogenous 
insulin production assessed by c-peptide measurement (38). This has been shown 
to be associated with less retinopathy and less hypoglycaemia during follow-up, 
making it an intriguing therapeutic target in the future (39).
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Insulin treatment can be given in different ways in order to achieve the general 
objective of lowering blood glucose to the near normal range of HbA
1c
, less than 
53 mmol/mol (or less than 7.0%). However, the blood glucose targets are always 
individual, and less or more stringent HbA
1c
 goals are sometimes appropriate. 
(40) Insulin can be administered through multiple daily injections or continuous 
subcutaneous insulin infusion (CSII) therapy. With multiple daily injections (i.e. 
basal-bolus therapy), long-acting basal insulin is injected once or twice a day, 
providing the basal insulin supplementation, and rapid-acting bolus insulin is given 
before meals based on carbohydrate intake. The aim is to mimic physiologic insulin 
and glucose profiles. However, studies have shown that a greater HbA
1c
 reduction 
can be achieved with continuous subcutaneous insulin infusions (41). In insulin 
pump therapy, there is a constant infusion of rapid-acting insulin, which can vary 
hour by hour to meet the individualised physiological needs. This is accompanied 
by additional bolus insulin administered by the patient before meals, as in the 
multiple daily injection therapy. Continuous glucose monitoring has resulted in 
a significant reduction in time spent in hypoglycaemia paralleled by a reduction 
in HbA1c compared to the self-monitoring of blood glucose (42). The most recent 
technological advancement in diabetes care is a hybrid closed loop system that 
integrates the insulin pump to deliver insulin and/or glucagon with continuous 
glucose monitoring systems, i.e. the artificial pancreas, which was approved by the 
FDA in 2016 (43). Studies regarding closed loop systems have shown promising 
results regarding the glycaemic control and the risk of hypoglycaemic events (44). 
Despite recent advancements, disease prevention, delay or cure, and the challenge 
to overcome the autoimmune nature of the disease, have proven surprisingly 
difficult. Although type 1 diabetes is a predictable disease, results from primary and 
secondary disease prevention studies have shown limited benefit so far (45, 46). For 
now, the goal of type 1 diabetes management is to achieve as close to normal blood 
glucose levels as possible without severe hypoglycaemia. The ultimate treatment 
goal, of course, is to prevent diabetic complications and improve the quality of 
life of the affected individuals. That goal requires a multidimensional approach, 
including optimal insulin treatment and management of risk factors, as well as a 
focus on healthy lifestyle. However, hopefully one day, the type 1 diabetes itself can 
be prevented or even cured.
2.2 Complications in type 1 diabetes 
Type 1 diabetes is a chronic condition involving long-term disease-associated 
complications leading to excess morbidity and mortality and is a huge cost 
burden to society (47–49). Generally, these complications are classified as micro- 
or macrovascular: damage to the small blood vessels leads to microvascular 
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complications (diabetic nephropathy, retinopathy and neuropathy). Macrovascular 
disease, including coronary artery disease, cerebrovascular disease and peripheral 
arterial disease, is the most common cause of premature death and disability among 
people affected by type 1 diabetes (50). 
One of the mainstays in the field of diabetic complications, Professor Michael 
Brownlee, proposed his unifying hypothesis for the development of both micro- and 
macrovascular complications in 2005. His theory suggested that hyperglycaemia 
induces oxidative stress, which is the unifying upstream event that activates the 
major metabolic pathways involved in diabetic tissue damage. Thus, mitochondrial 
overproduction of reactive oxygen species (ROS) causes damage via four major 
mechanisms: the polyol pathway, the hexosamine pathway, the production of 
advanced glycation end products (AGEs), and the activation of protein kinase C 
(PKC). Insulin resistance may further accelerate the glucose-induced tissue damage 
in macrovascular disease. (51)
Figure 1. The Brownlee hypothesis. Modified from Brownlee et al., “The Pathobiology of Diabetic 
Complications”, Diabetes (2005) (51).
2.2.1 Diabetic nephropathy 
2.2.1.1 Definition, diagnosis and renal function
Diabetic nephropathy is the most common cause of chronic kidney disease (CKD) 
worldwide and accounts for the increased risk of premature mortality associated with 
type 1 diabetes (6). The natural history of diabetic nephropathy commences from 
subclinical disease characterised by renal hyperfiltration followed by the occurrence 
of persistent microalbuminuria. Later, the disease is characterised by a gradual 
decline of the GFR and increased leakage of albumin into the urine, eventually 
leading to the final stage of end-stage renal disease (ESRD).
Screening for microalbuminuria is the cornerstone of finding patients at risk for 
diabetic nephropathy. The urinary albumin excretion (UAER) is measured either 
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from a 24-hour or a timed overnight urine collection, and the patient is diagnosed if 
they have two positive samples out of three consecutive diagnostic measurements. 
The earliest sign of diabetic nephropathy is microalbuminuria (≥20 μg/min or ≥30 
mg/24 h), and its presence is a strong predictor of progression to macroalbuminuria 
or overt nephropathy (defined as an UAER of ≥200 μg/min or ≥300 mg/24 h) and 
eventually to ESRD, defined as the demand for dialysis or renal transplant. (52, 53) 
The 24-hour urine collection has been regarded as the gold standard, although a 
more convenient and commonly used method to detect microalbuminuria is the 
albumin (μg)/creatinine (mg) ratio measured in a random urine sample. Earlier 
studies demonstrated microalbuminuria as a stride towards the later sequential 
stages of diabetic nephropathy, but more recent studies suggest that, in a substantial 
proportion of the individuals with type 1 diabetes, microalbuminuria can indeed 
regress (54). Some individuals may even follow a nonalbuminuric pathway to 
diabetic nephropathy, and in such cases, the GFR decline may have started even 
before the onset of albuminuria (55). Therefore, a new model was recently suggested 
in which the clinical feature of diabetic nephropathy in type 1 diabetes is progressive 
renal decline and not albuminuria (56). In fact, in type 2 diabetes, this phenomenon 
is common: as much as 30–57% of patients with chronic kidney disease (CKD) are 
normoalbuminuric (57–59). On the other hand, nonalbuminuric CKD is uncommon 
in type 1 diabetes and was found in only 2% of individuals with type 1 diabetes in the 
FinnDiane Study (60). In addition, normoalbuminuric CKD in this cohort was seen 
in elderly females and was predictive of cardiovascular disease rather than kidney 
disease. Nevertheless, microalbuminuria plays an essential diagnostic role in the 
assessment of early diabetic nephropathy and is the best non-invasive predictor of 
progression. In addition, microalbuminuria independently predicts cardiovascular 
morbidity and mortality (6, 61, 62). 
A decrease in the glomerular filtration rate (GFR) to <60 mL/min/1.73 m2 
for three months or more is commonly used as a diagnostic criterion for CKD. 
Indirect measurement of GFR by inulin clearance during continuous inulin infusion 
is considered the gold-standard method for measuring renal function (63). However, 
this method is not feasible in the general clinical practice. Therefore, other markers 
and methods are being used to estimate renal function in both clinical practice 
and research. The most widely used methods are estimates based on the serum 
creatinine level: the Cockcroft-Gault formula (64), the Modification of Diet in Renal 
Disease (MDRD) (65), and the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation (66). At the time, the most recent CKD-EPI equation is the 
most accurate GFR estimating equation that has been evaluated in large diverse 
populations and has, therefore, been proposed to replace the MDRD equation in 
clinical practice (67). Renal function is divided into five categories based on the 
estimation of the GFR (eGFR) (Table 1).
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Table 1. The staging of CKD and GFR categories (National Kidney Foundation)
and has, therefore, been proposed to replace the MDRD equation in clinical practice 
(67). Renal function is divided into five categories based on the estimation of the GFR 
(eGFR) (Table 1). 
 
Table 1. The staging of CKD and GFR categories (National Kidney Foundation) 
 
Stage GFR ml/min/1.73 m2  Description 
1 ≥90 Normal or high  
2 60–89 Mildly reduced  
3a 45–59 Mildly to moderately 
reduced 
3b 30–44 Moderately to severely 
decreased 
4 15–29 Severely decreased 




2.2.1.2 Epidemiology  
 
The presence of DN is associated with an increased risk of CVD, and it is the leading 
cause of renal failure and increased mortality among patients with type 1 diabetes in 
the developed world (68). About one-third of the individuals with type 1 diabetes 
develop DN. At first, the incidence increases linearly with the duration of diabetes, 
but 20–25 years after diagnosis of diabetes, the incidence begins to decline. However, 
the overall incidence of DN and ESRD has decreased, especially in individuals most 
recently diagnosed with type 1 diabetes, a phenomenon probably due to improved 
care. (54, 69, 70). In Finland, the incidence of ESRD has also decreased, and the 
cumulative incidence for the development of ESRD within 30 years is approximately 
7.8% (71). It should be noted that, since the earliest studies in the 1980s, there is now 
a delay of 10 or more years in the appearance of ESRD, although there are differences 
between regions and even among the European countries (72). Previously, 
approximately 80% of the individuals with microalbuminuria developed overt 
proteinuria (52, 53), whereas our own data a few years later showed a much lower 
progression rate of 28% in individuals with a duration of diabetes over 15 years (73). 
As described earlier, even more than a third of individuals with microalbuminuria 
may regress to a normal albumin excretion rate, emphasizing the importance of early 




Genetic predisposition, accompanied by environmental factors and the diabetic 
milieu, leads to structural and functional abnormalities in DN. Functional and 
haemodynamic abnormalities include early glomerular hyperfiltration, glomerular 
hypertension (i.e. increased intraglomerular pressure), increased permeability of the 
basement membrane, shear stress and increased albumin excretion. As nephropathy 
progresses, the proteinuria increases and the GFR deteriorates. (76) In addition, 
hyperglycaemia induces the production of humoral mediators, cytokines and growth 
factors, resulting in structural changes such as glomerular mesangial expansion and 
thickening of the glomerular basement membrane. As the disease progresses, 
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2.2.1.3 Pathogenesis
Genetic predisposition, accompanied by environmental fac ors and the iabetic 
milieu, leads to structural and functional abnor alities in DN. Functional and 
haemodynamic abnormalities include early glomerular hyperfiltration, glomerular 
hypertension (i.e. increased intraglomerular pressure), increased permeability of the 
basement membrane, shear stress and increased albumin excretion. As nephropathy 
progresses, the proteinuria increases and the GFR deteriorates. (76) In addition, 
hyperglycaemia induces the production of humoral mediators, cytokines and growth 
factors, resulting in structural changes such as glomerular mesangial expansion 
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and thickening of the glomerular basement membrane. As the disease progresses, 
mesangial expansion typically presents as glomerulosclerosis, with characteristic 
nodular lesions called the Kimmelstiel-Wilson nodules. Tubulointerstitial injury 
develops alongside the glomerular damage. In the early stages of diabetic 
nephropathy, tubular hypertrophy is present, but thereafter, interstitial fibrosis 
with tubular atrophy develops, accompanied by arteriolar hyalinosis. (77,78)
Several pathophysiological pathways are involved in the development of 
diabetic nephropathy. A hormonal system that regulates blood pressure and fluid 
homeostasis, i.e. the renin-angiotensin-aldosterone system (RAAS) is an essential 
element in the pathogenesis of DN (78,79). Hyperglycaemia induces the production 
of angiotensin II, the main peptide of the RAAS, as well as extracellular matrix 
accumulation by mesangial cells, primarily via stimulation of transforming growth 
factor-β (TGF-β) expression. TGF-β has been viewed as a key player in mediating 
the profibrotic and hypertrophic effects of various pathological stimuli. (80, 81) In 
addition, angiotensin II constricts the efferent arteriole in the glomerulus, leading 
to higher glomerular capillary pressures and direct podocyte injury through the 
generation of ROS and an increased influx of calcium. Notably, there is inappropriate 
overproduction of angiotensin II predisposing to hypertension, a condition that 
often accompanies diabetes and accelerates the progression of diabetic nephropathy. 
(77-79) Moreover, renal hyperfiltration is an early haemodynamic abnormality 
associated with increased glomerular pressure and potentially the development 
of diabetic nephropathy. The most recent oral glucose-lowering agents, sodium-
glucose cotransporter 2 inhibitors, have shown renal protection by normalising 
hyperfiltration via tubuloglomerular feedback. (82) There are several other known 
complex pathways overlapping and interacting with one another and thereby 
contributing to the development of DN. Hyperglycaemia, the main driver of the 
development of DN, results in the up-regulation of the glucose transporter GLUT-1, 
further induced by increased intraglomerular pressure, Ang-II and an abnormal 
stimulation of renal cells to produce more TGF-β1, thereby amplifying the loop of 
glucotoxicity. Hyperglycaemia induces vascular injury through the generation of 
superoxide, hydroxyl radical, hydrogen peroxide and peroxynitrite, all commonly 
referred to as ROS. (83,84) Oxidative stress has been suggested as the unifying 
mechanism in the pathogenesis of DN via different metabolic pathways: the polyol 
pathway, hexosamine pathway, the production of AGEs and activation of PKC, as 
pointed out above (84–86). Other factors that contribute to the pathogenesis of 
DN include the elaboration of proinflammatory cytokines and activation of growth 
factors such as connective tissue growth factor, insulin-like growth factor-1 and 
vascular endothelial growth factor (87, 88).
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2.2.1.4 Risk factors 
Several risk factors have been shown to contribute to the development of DN in 
individuals with type 1 diabetes. Risk factors such as hyperglycaemia, high blood 
pressure, dyslipidaemia, insulin resistance and smoking are supported by a poorly 
characterised genetic background. However, the genetic factors are likely to increase 
susceptibility to the complication. For example, familial aggregation of DN is shown 
in studies regarding both type 1 and type 2 diabetes, and a parental history of 
hypertension or CVD predicts its development (89–93). There are also differences 
in the incidence of DN between groups of different ethnic backgrounds (94, 95). 
Furthermore, in the Wisconsin Epidemiologic Study, Klein et al. showed that a 
large proportion of individuals with type 1 diabetes did not develop DN despite 
severe and chronic hyperglycaemia (96). Some of the risk factors will be discussed 
in detail below.
Glucose
An elevated blood glucose concentration is a prerequisite for the development 
of DN. Several studies have shown that, by improving the glycaemic control in 
individuals with type 1 diabetes, their risk of diabetic nephropathy during follow-
up is substantially reduced. The landmark Diabetes Control and Complications 
Trial (DCCT) established the importance of glycaemic control and confirmed the 
previous findings from the Steno, Oslo and Stockholm studies, which showed 
renal benefits through the lowering of HbA1c (97–100). These data resulted in 
a global change in the management of type 1 diabetes. The DCCT randomised 
1441 individuals with type 1 diabetes to receive either intensive or conventional 
glucose-lowering therapy and confirmed the importance of optimal blood glucose 
control in order to reduce the risk of complications in type 1 diabetes. Over 6.5 
years of follow-up, intensive glycaemic control (median HbA1c, 7.2% vs. 9.1% in 
the conventionally treated group) reduced the cumulative incidence and overall risk 
of microalbuminuria by 39% and macroalbuminuria by 54% in both the primary 
prevention and secondary intervention groups. Observational follow-up data on the 
same patients after the close-out of the DCCT showed that, although the HbA1c 
levels were similar during the EDIC (Epidemiology of Diabetes Interventions and 
Complications) study follow-up, the risk of DN in the former intensively treated 
group was significantly lower than in the conventionally treated group. This 
indicated that exposure to hyperglycaemia during DCCT was remembered in the 
“metabolic memory”, and based on this observation, it is important to establish 
stringent glycaemic control early in the course of type 1 diabetes (101). On the 
other hand, the most significant side effect of tight glycaemic control was severe 
hypoglycaemia, which highlights the importance of individualised treatment. It 
is of note that patients with the same HbA1c levels might have markedly different 
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glucose profiles with frequent hypo- and hyperglycaemic values, and thus, glucose 
variability may be an additional risk factor for the development of complications, 
particularly diabetic nephropathy. Interestingly, a retrospective analysis of the data 
from the DCCT led to the consideration that glycaemic variability may influence 
the development of complications in type 1 diabetes apart from the mean HbA1c 
(102). More recent data supported the initial finding that glycaemic variability may 
be important in the development of diabetic nephropathy in type 1 diabetes, but 
larger prospective outcome studies are required to verify these preliminary findings 
(103, 104). In addition, recent data from the DCCT showed that the time in range of 
70–180 mg/dL (3.9–10 mmol/L) was strongly associated with reduced microvacular 
complications (105).  
Hypertension
Hypertension is common in individuals with type 1 diabetes, even in those without 
renal involvement, but it is definitely more common in those individuals, who 
progress to microalbuminuria (106, 107). Blood pressure contributes considerably 
to the development and progression of diabetic nephropathy and is associated with 
both the increase of proteinuria and the decrease of renal function (108, 109). The 
prognosis of DN has improved in recent decades – largely because hypertension 
is being more aggressively treated (110). A recent meta-analysis suggested that 
angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARB) 
were the most effective strategies against ESRD (111). Also, current international 
blood pressure management guidelines suggest that these agents are similarly 
effective in the prevention of renal failure in individuals with CKD, but it should 
be noted that combining them is not recommended due to an excess of renal adverse 
events (112). RAAS inhibition is renoprotective, even in normotensive type 1 diabetes 
individuals with microalbuminuria. Interestingly, the Bergamo Nephrologic Diabetes 
Complications Trial (BENEDICT) showed that RAAS inhibition prevented the onset 
of microalbuminuria in type 2 diabetes (113). However, whether microalbuminuria 
could be prevented by RAAS inhibition in type 1 diabetes is still unknown. So far, 
studies have not shown this benefit in type 1 diabetes (114).
Insulin resistance
Insulin resistance, which is related to hypertension, dyslipidaemia and cardiovascular 
events, has also been proposed to play a central role in the development and 
progression of diabetic nephropathy. There are several studies supporting this 
proposal. The Pittsburgh Epidemiology of Diabetes Complications (EDC) Study 
showed that insulin sensitivity measured by the estimated glucose disposal rate 
predicted DN (115). In addition, it has been shown that insulin sensitivity is 
associated with microalbuminuria by using the euglycaemic hyperinsulinaemic 
clamp technique, the gold standard in measuring insulin sensitivity (116–118). 
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Obesity
Obesity is highly prevalent and is a growing problem in individuals with type 
1 diabetes (119). In fact, several studies have shown an association between 
the metabolic syndrome (visceral obesity, dyslipidaemia, hyperglycaemia and 
hypertension) and the risk of DN in type 1 diabetes (120, 121). In the general 
population, the relative risk of ESRD increases progressively with the degree of 
overweight/obesity, and some studies also show an association between obesity and 
DN in type 1 diabetes (122–125). These data were recently replicated and extended 
to show a causal relationship between obesity and diabetic nephropathy by our 
own research group (126).  
Other risk factors 
Several other risk factors contribute to the development of DN in type 1 diabetes. 
Data from the FinnDiane Study show that dyslipidaemia predicted the initiation 
and progression of diabetic nephropathy at all stages of renal disease in type 1 
diabetes (127–129). In line with these findings, dyslipidaemia has been shown to 
associate with renal disease in the DCCT/EDIC, EURODIAB and Estudio Diamante 
cohorts (130–132). Other risk factors such as smoking (133), inflammatory markers 
(134, 135), male gender (136), low birth weight (137) and short adult stature are 
also associated with the development of diabetic nephropathy in type 1 diabetes 
(138, 139).
2.2.2 Diabetic Retinopathy
Diabetic nephropathy and diabetic retinopathy are closely associated. Diabetic 
retinopathy results from damage to the small blood vessels and neurons in the 
retina and is a leading cause of blindness in developed countries (140). It was 
estimated that, in the USA, 86% of the individuals with type 1 diabetes have diabetic 
retinopathy, and about one-half have vision-threatening retinopathy (141). Likewise, 
high prevalence estimates have been reported in other countries (142). Eventually, 
as the duration of their diabetes gets longer, all individuals with type 1 diabetes will 
develop some degree of retinopathy (143). However, there has been a significant 
reduction in the incidence, progression and prevalence of diabetic retinopathy over 
the past several decades in individuals with a more recent diagnosis of type 1 diabetes 
due to improved treatment of dyslipidaemia, hypertension and hyperglycaemia 
(144, 145). Consequently, in the WESDR study, the estimated annual incidence of 
proliferative diabetic retinopathy decreased by 77% and vision impairment by 57% 
between 1980 and 2007 (146, 147). 
Along with the risk of vision loss, diabetic retinopathy is accompanied by a higher 
risk of mortality and systemic vascular complications, including stroke, coronary 
heart disease, heart failure and DN (148). The most firmly established risk factors 
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for diabetic retinopathy are diabetes duration (149) and hyperglycaemia (150). 
Hypertension is an important modifiable risk factor (151), and diabetic retinopathy 
is further associated with risk factors such as obesity (152), dyslipidaemia (153), 
pregnancy (154) and puberty (155, 156). 
The asymptomatic first stage of diabetic retinopathy, called non-proliferative 
diabetic retinopathy, is characterised by the presence of early intraretinal 
microvascular findings of microaneurysms, haemorrhages, retinal oedema, lipid 
exudates and microinfarcts (157). These are found in almost all individuals with type 
1 diabetes after 20 years of diabetes (143). Treatment of blood pressure, optimal 
serum lipid and glycaemic control can delay the onset and slow the progression 
of non-proliferative diabetic retinopathy to the later-stage sight-threatening 
neovascularisation of the retina designated as proliferative retinopathy. 
Macular oedema can occur at any stage of diabetic retinopathy and can lead to 
blindness. It is characterised by macular swelling caused by the leakage of fluids 
and lipids into the macula from damaged blood vessels (158). Diabetic retinopathy 
is diagnosed with fundus photography or direct ophthalmoscopy. For adults, 
international guidelines advocate for diabetic retinopathy screenings five years 
after the diabetes diagnosis (159). 
The DCCT, the UK Prospective Diabetes Study (UKPDS), and the Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study have shown that 
intensive glycaemic control reduces the risk of development and progression of 
diabetic retinopathy (150, 151, 160). In the DCCT trial, even though the mean HbA1c 
levelled off during the observational follow-up, the benefit of the intensive treatment 
persisted (161). The UKPDS study showed that lowering the mean systolic blood 
pressure (SBP) from 154 mmHg to 144 mmHg slowed the progression of diabetic 
retinopathy in individuals with type 2 diabetes (160). Findings from observational 
studies further suggest that dyslipidaemia is associated with the progression of 
diabetic retinopathy (158). Thus, the comprehensive treatment of all risk factors for 
diabetic retinopathy constitutes the foundation of the prevention and management 
of the complication (151). Finally, interventions such as laser photocoagulation, 
vitrectomy and injections of anti-vascular endothelial growth factor are effective 
for the prevention of visual impairment in more advanced stages of diabetic 
retinopathy (severe non-proliferative retinopathy, proliferative retinopathy and 
macular oedema) (158).
2.2.3 Diabetic neuropathy
Diabetic neuropathy refers to nerve damage associated with diabetes and confers 
the increased risk of other diabetic complications and premature mortality (162). 
The estimated prevalence for diabetic neuropathy ranges widely based on the 
study population and definition of diabetic neuropathy. Microvascular injury to 
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the blood vessels supplying nerves and nerve damage results in diverse clinical 
manifestations. Risk factors for diabetic neuropathy include hyperglycaemia, long 
diabetes duration, diabetic retinopathy, microalbuminuria, obesity, smoking, 
dyslipidaemia, hypertension and tall stature (163–167). 
Different classifications of diabetic neuropathy have been proposed throughout 
the history of diabetes. Currently, the most common way to classify diabetic 
neuropathies is to divide them into two major forms: generalised and focal 
neuropathy. The most common form is chronic sensorimotor distal symmetric 
polyneuropathy (DPN), which is diagnosed by clinical tests such as vibration 
perception, 10-g monofilament perception, temperature perception and ankle 
reflex testing. Individuals with five years or more of type 1 diabetes should be 
assessed annually. Early detection of DPN together with peripheral arterial disease is 
important to prevent foot ulcers and, consequently, limb amputation since a major 
proportion of patients with DPN may be asymptomatic. (168) About 40–60% of 
individuals that have documented neuropathy suffer from neuropathic pain (169). 
However, this might be an underestimation since patients often do not mention 
these symptoms to their attending physicians (170). 
Among the neuropathies, cardiac autonomic neuropathy (CAN) is the most 
studied and the most clinically significant diabetic autonomic neuropathy. The 
prevalence of CAN increases with the duration of diabetes, and prevalence rates 
of at least 30% were observed in the DCCT/EDIC cohort after 20 years of diabetes 
onset (171–173). Several longitudinal studies have shown that CAN is associated 
with significant increases in morbidity and mortality (174-178). Consequently, 
CAN is an independent risk factor for cardiovascular mortality, arrhythmias, 
silent ischaemia, major cardiovascular events and myocardial dysfunction. (174–
179) Importantly, CAN may cause exercise intolerance and may also increase the 
risk of exercise-related sudden death (180, 181). Hyperglycaemia is the major risk 
factor for CAN (182, 183), and the DCCT/EPIC trials showed that glucose control 
with a near-normal glycaemia target substantially reduces the incidence of CAN in 
individuals with type 1 diabetes (184). Other risk factors associated with CAN are 
age, elevated blood pressure and presence of other diabetic complications (185–188). 
Typically, the early stages of CAN are asymptomatic, and the earliest finding is a 
decrease in heart rate variability, which can be detected by a deep breathing test. 
Later, resting tachycardia, symptoms of orthostatic hypotension and abnormal 
blood pressure profile, arrhythmias and exercise intolerance may appear. Other 
neuropathies include typical focal neuropathies such as carpal tunnel syndrome, 
diabetic amyotrophy and nerve palsies. (189)
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2.2.4 Macrovascular complications 
Macrovascular complications of diabetes include coronary artery disease (CAD), 
cerebrovascular disease and peripheral arterial disease (PAD). Atherosclerosis is 
at the core of the pathogenesis of these complications. In the majority of studies 
regarding CVD and type 1 diabetes, the outcomes are pooled together in a common 
CVD endpoint. CAD is the most common and studied macrovascular complication 
of diabetes, and there are fewer data on cerebrovascular disease and peripheral 
arterial disease in type 1 diabetes. Individuals with type 1 diabetes are at substantially 
increased risk of premature mortality, and cardiovascular disease (CVD) is the most 
important cause of death in these individuals (50). Altogether, CVD is more common 
and occurs earlier in type 1 diabetes than in the general population. For example, in 
the UK’s General Practice Research Database (GPRD) study, CVD events developed 
10–15 years earlier than in the matched control subjects without diabetes (190). 
The risk of CVD in type 1 diabetes varies among study cohorts. Several studies show 
that the age-adjusted relative risk for CVD in type 1 diabetes is around 10 times 
higher than that of the general population (191–193). 
The presence of diabetic nephropathy is strongly associated with CVD. In the 
Steno cohort, there was a 4.2-fold increase in the relative risk of CVD mortality in 
individuals with type 1 diabetes without proteinuria and a 37-fold increase in the 
risk of CVD mortality in those with proteinuria compared to the general population 
(194). Interestingly, in the FinnDiane Study, individuals with type 1 diabetes with 
normal UAER had a similar standardised mortality rate to the general population. 
However, individuals with microalbuminuria showed a 3-fold higher risk of all-cause 
mortality, and those with ESRD had an 18-fold higher risk during follow-up. (6) A 
similar finding was also observed in the Pittsburgh cohort, in which the presence 
of microalbuminuria or DN accounted for the increased cardiovascular mortality 
in type 1 diabetes (195). Notably, there is a decreasing trend regarding all-cause 
mortality and the incidence of cardiovascular complications in type 1 diabetes. Such 
decreasing incidence rates were recently shown in the Swedish nationwide registry 
data and were coherent with trends observed in other studies in North America 
and Europe (194, 196–200). However, there has been a more significant decline in 
the incidence of DN in type 1 diabetes in recent decades than in the CVD events, 
suggesting that these complications are not identical even though share risk factors 
(201). In the general population, female gender is known to protect from CVD. 
However, in type 1 diabetes, the protective effect seems to be eliminated. A number 
of studies have shown similar rates of CVD events in both genders (202–206), but 
one study showed that the relative mortality risk for women with CAD was 40-fold 
compared to the general population, whereas for men, it was 10-fold higher (207). 
Also, a family history of type 2 diabetes or CVD events is associated with CVD 
events in type 1 diabetes (208, 209).
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Previous observational data suggest that dysglycaemia is a risk factor for 
CVD events in type 1 diabetes, although the published studies have shown some 
inconsistencies. The EURODIAB study showed an association with hyperglycaemia 
and coronary heart disease only in men with type 1 diabetes (210). In the WESDR 
study, glycaemic control was independently associated with overall CVD mortality 
but not with myocardial infarction (211), and in the Pittsburgh Epidemiology of 
Diabetes Complications (EDC) Study cohort, there was no association between 
hyperglycaemia and coronary heart disease (212). However, at a later stage, an 
association was found with CVD mortality (215). Finally, data from the DCCT/EDIC 
demonstrated that a mean of 6.5 years of intensive therapy with a mean HbA1c of 
~7% compared with conventional therapy with an HbA1c of ~9% was associated 
with a 42% risk reduction in all cardiovascular events. Moreover, there was a 57% 
reduction in the risk of non-fatal MI, stroke or death from CVD after an additional 
11 years of observational follow-up in the EDIC study, independent of DN (213). 
Hyperglycaemia measured as the mean HbA1c was a clear risk factor for CVD events, 
even after 27 years of observational follow-up, suggesting the importance of early 
intensive glycaemic management of CVD events (214). 
Other risk factors for CVD in type 1 diabetes include hypertension, dyslipidaemia, 
obesity, insulin resistance, inflammation and smoking, which are also classical risk 
factors for CVD in type 2 diabetes and the general population. In addition, age and 
diabetes duration also play a significant role in the development of macrovascular 
disease. The reduction of the risk of macrovascular disease requires a multifactorial 
treatment strategy, including smoking avoidance, optimal glycaemic, blood pressure, 
weight and lipid control, as well as the use of targeted medical agents like RAAS-
blockers and statins. (201)
2.3 Physical activity
2.3.1 Definition of physical activity 
The most widely used definition of physical activity, written by Caspersen et al. 
in 1985, is “any bodily movements produced by skeletal muscles that result in 
energy expenditure” (216). There are various ways to categorise physical activity. One 
simple approach is to classify physical activity according to the different sections of 
general daily life: occupational, transportational and leisure-time physical activity 
(LTPA), i.e. physical activity performed during leisure or discretionary time. LTPA 
can be further divided into categories such as sports, household tasks etc. Although 
these terms are often confounded, exercise is a subset of physical activity (216) and 
refers to any planned, structured and repetitive physical activity with the objective 
of improving fitness, health or performance (217). Physical activity may improve 
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physical fitness, which is generally considered the ability to function efficiently and 
effectively in various activities and emergency situations. It consists of health-related 
attributes, such as body composition, flexibility, cardiorespiratory and muscular 
endurance and strength (216). Activities have different components including type, 
frequency, intensity and duration (218). Physical activity is usually classified as either 
anaerobic or aerobic, depending on the dominant energy system used for energy 
supply. Aerobic exercise generally includes low-to-moderate intensity activities that 
are supported by aerobic fuel metabolism, such as jogging, swimming and cycling. 
Anaerobic exercise, such as weight lifting or sprinting, includes short, high-intensity 
activities that do not depend on oxygen as an energy source. However, most activities 
include a combination of both aerobic and anaerobic energy systems. (217)
2.3.2 Assessment of physical activity
As clear evidence of an association between physical activity and the inverse risk of 
many chronic diseases is continuously growing, the need and interest in physical 
activity assessment among different research fields has increased. Contrary to other 
documentable or measurable risk factors such as hypertension or smoking, physical 
activity is relatively challenging to measure in comparison. Over 30 different ways 
of estimating and measuring physical activity are and have been used in research, 
and no consensus of a gold-standard method exists. Heterogeneous methodology 
also leads to challenges when studies are compared and their results interpreted. 
Daily energy expenditure depends on basal metabolic rate (50–70%), the 
thermic effect of food (10%) and the most variable component: physical activity. 
Energy expenditure is generally expressed as kilocalories (kcal) or by using the 
metabolic equivalent (MET) of the activity, which is defined as multiples of the 
energy expenditure at rest. The basal rate of oxygen consumption and associated 
caloric cost is approximately 3.5 ml/kg/min, or about 1 kcal/kg/h, which is assumed 
to be 1 MET; other activities can be expressed as multiples of the basal 1 MET. (218) 
However, the MET values also have limitations: age and obesity alter the metabolic 
rate. For example, children consume more oxygen relative to their body mass at 
rest, whereas in the elderly, the basal metabolic rate is typically lower (219). The 
doubly labelled water (deuterium and oxygen-18) technique is considered the most 
precise method for assessing the energy expenditure of physical activity (220). Its 
use has increased vastly since 1982, when the first study using this technique in 
humans was published. The technique is based on the estimation of the rate of 
carbon dioxide elimination from the body (221). However, the method is very costly 
and therefore not applicable to large study populations (220). 
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Table 2: Examples of MET values for different types of activities and recommended intensity 
level category according to the “Position statement on physical activity and exercise intensity 
terminology” by K. Norton et al. Table modified from Norton K. et al., Journal of Science and 
Medicine in Sport (2010) (222) and Ainsworth B.E. et al., Medicine & Science in Sports & Exercise 
(2011) (223).
elimination from the body (221). However, the method is very costly and therefore 
not applicable to large study populations (220).  
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MET level  Example activities  Intensity category 
<1.6 METs Standing in line, watching 
TV, riding in a car 
Sedentary 
1.6<3 METs Household walking, 
playing darts  
Light 
3<6 METs Mopping, vacuuming, 
low-impact aerobics, brisk 
walking 
Moderate 
6<9 METs  High-impact aerobics, 
basketball, horse racing 
(galloping) 
Vigorous 
9<11 METs Rope jumping (moderate), 
kickboxing, water polo, 
soccer (competitive) 
High 
11<16 METs Skin diving, vigorous 
stationary rowing (200W), 
running 8 mph 
 
 ≥16 METs 
Running >10 mph, 




Physical activity assessment tools and methods can be classified as subjective or 
objective. Subjective methods include recall questionnaires and diaries or logs, in 
which an individual records the activities just after they are performed. There are 
numerous questionnaires used in research, varying both in question detail and recall 
time, ranging from hourly to life-time frames. These self-report methods are non-
invasive and are mostly used in large epidemiological studies for practical and 
economic reasons. (218,219) However, these subjective questionnaires have 
limitations such as human recall and social desirability bias (219). Activity diaries 
aim to minimise memory errors, but they might increase physical activity above 
habitual levels during the examination period (220). Therefore, questionnaires with 
activity recall for longer periods of time might better reflect the habitual activity of an 
individual (218-220, 224, 225). 
Objective methods to measure physical activity are usually based on different 
devices or applications, including motion sensors such as accelerometers and 
pedometers, heart rate monitors, direct observation, indirect calorimetry and doubly 
labelled water (219, 220). Novel objective measurement devices utilise multiple 
parameters to measure physical activity (225). Objectively measuring physical 
activity is regarded to be more accurate than subjective methods, but it is also more 
expensive and therefore not feasible in larger settings. In large study populations, 
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objective. Subjective methods include recall questionnaires and diaries or logs, in 
which an individual records the activities just after they are performed. There are 
numer estio naires used in research, varying both in question detail nd 
recall time, ranging from hourly to life-time frames. These self-report methods 
are non-invasive and are mostly used in large epidemiological studies for practical 
and economic reasons. (218,219) However, these subjective questionnaires have 
limita ions such as human recall and social desirability bias (219). Activity diari s 
aim to minimise memory errors, but they might increase physical activity above 
habitual levels during the examination period (220). Therefore, questionnaires with 
activity recall for longer periods of time might better reflect the h bitual activity of 
an individual (218-220, 224, 225).
Objective methods to measure physical activity are usually based on different 
devices or applications, including motion sensors such as accelerometers and 
pedometers, heart rate nitors, direct observation, indirect calorimetry and 
doubly labelled water (219, 220). Novel objective measurement devices utilise 
multiple parameters to measure physical activity (225). Objectively measuring 
physical activity is regarded to be more accurate than subjective methods, but 
it is also more expensive and therefore not feasible in larger settings. In large 
study populations, objective methods are mainly used in subsets to validate the 
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questionnaire used (219). It is noteworthy that all devices and methods share 
potential biases of increased activity during the measurement period (218-220, 
224, 225). Interestingly, modern technology has provided a novel and potentially 
feasible possibility of objective measurement: e.g. a recent study used smartphones 
with built-in accelerometry to measure physical activity patterns in different 
populations worldwide (226).
2.3.3 Physiology
Energy supply is the prerequisite for basic metabolism and physical activity. The 
body has the ability to convert chemical energy derived from food (carbohydrates, 
fats and proteins) and sufficient oxygen delivery to adenosine triphosphate (ATP), 
a molecule that is stored mainly in the muscle cells. During muscle contraction, 
the required energy is provided by ATP and is broken down by myosin ATPase. 
The skeletal muscle can increase its energy consumption over 100-fold in response 
to contraction. This energy is derived mainly from liver glycogen, adipose tissue 
triacylglycerol and local muscle stores of glycogen and triacylglycerol. There are 
three main metabolic pathways that provide a continuous supply of ATP for muscle 
contraction. Interestingly, these systems overlap, and the dominating system 
depends on the intensity and duration of the activity. The first system is anaerobic 
and uses ATP and phosphocreatine as energy sources. This is important for the onset 
of exercise, as it is sufficient enough to support intense contractions just for the first 
seconds, before other metabolic pathways take over. As exercise continues, anaerobic 
glycolysis converts muscle glycogen to glucose and then to lactate, providing quick 
energy but a relatively low ATP yield. Therefore, the muscle glycogen stores are 
quickly depleted, which limits intense activity duration to approximately 1 minute. 
The lactate acid leads to a drop in pH levels, resulting in the impairment of muscle 
contraction and muscle fatigue, felt as “burning”. The third oxygen-dependent 
pathway, following an increased blood flow and oxygen delivery, utilises glucose, 
lactate and fatty acid oxidation. This yields ATP for long-term aerobic activities. (227) 
The main sources for energy during muscular exercise are fat (triglyceride) 
and carbohydrate (glycogen and glucose). The contribution of protein as a fuel is 
relatively small. The proportion of fat vs. glucose utilisation varies greatly due to 
many factors, e.g. meal timing and consistency before exercise, fitness level, glycogen 
stores, duration and intensity of exercise. Fat is an important fuel during light to 
moderate exercise, providing at least half the energy. In prolonged exercise, this 
proportion can increase up to 80%. Carbohydrate is increasingly vital during high-
intensity exercise or bouts. It is also important in energy and exercise metabolism, 
sparing protein breakdown, functioning as a primer in fat utilisation and as an 
energy source for the brain. The glucose source for muscles is glycogen from muscle 
and liver stores and from circulating blood glucose derived mainly from the liver. 
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During activity, the muscles increase their glucose uptake up to 40-fold, while other 
tissues decrease their glucose uptake. (227) 
The skeletal muscle is insulin sensitive. However, the increased glucose uptake is 
elevated due to both insulin-dependent and insulin-independent mechanisms (228). 
Physical activity increases the recruitment of glucose transporters to the surface of 
muscle cells. This process is stimulated by both insulin and muscle contractions 
through distinctive signalling pathways, and these stimuli have a cumulative effect 
(229). The increased glucose uptake should be balanced by hepatic glucose output, 
increasing gluconeogenesis and glycogen mobilisation to keep the blood glucose at an 
adequate level. In addition, free fatty acids in the blood and lipolysis are increased. 
The main hormonal responses to maintain plasma glucose include increased 
levels of catecholamines (epinephrine and norepinephrine), glucagon, cortisol, 
growth hormone and a decrease in insulin release. The responses vary substantially 
according to the intensity and duration of the exercise. These hormonal responses 
are discussed in more detail in chapter 2.4.1.  
2.3.4 Physical activity: health benefits and the risks of inactivity
It is well documented that physical activity leads to various significant health benefits 
in both primary and secondary prevention of several chronic diseases and mortality. 
The first studies are from the 1950s, when Morris et al. showed that the incidence 
of CAD was higher among sedentary drivers than among more physically active bus 
conductors (individuals collecting fares and selling tickets) (230). In the following 
decades, Paffenbarger and colleagues expanded these results (231–233). 
In recent years, there has been a growing amount of evidence about the effect of 
physical activity on the primary and secondary prevention of CVD. The results of a 
recent meta-analysis and review are in line with the previous evidence. Both LTPA 
and occupational physical activity reduce the risk of incident CAD and stroke by 
10–30% (234). In addition, the benefits of physical activity and fitness also apply 
to patients with established CVD (7). Regarding all-cause and cardiovascular death, 
observational data show that physical activity and a high fitness level are associated 
with a reduced risk of mortality, and there seems to be a dose-response relationship 
(7). However, it is noteworthy that the findings are mainly limited to Caucasian 
individuals in Western countries (233). 
In general, a higher amount of physical activity is positively associated with the 
key risk factors for CVD, many of which are mutual to other chronic diseases, as 
indicated in the pathogenesis of diabetic complications. Physical activity is beneficial 
for lowering blood pressure and for improvement of the lipid profile (235). Evidence 
shows that physical activity also improves insulin sensitivity (236), endothelial 
function (237), glucose homeostasis (238) and autonomic function (239), and it 
decreases blood coagulation (240) and inflammation (241). Physical activity has 
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been shown to decrease both body fat and weight and improve fat distribution 
(235). In addition, other health benefits of physical activity include reduced risk 
for osteoporosis and cancer, improvement of mental well-being and prevention of 
cognitive decline (7, 242, 243).  
Regarding type 2 diabetes, there is solid evidence about physical activity in 
both primary and secondary prevention (8–10, 244). Randomised control trials 
have shown that lifestyle interventions, including physical activity and dietary 
intervention, provide a substantial benefit leading to disease delay and potential 
disease prevention (245). Also, exercise interventions have shown benefits regarding 
glucose control in individuals with T2D (246), and observational studies have shown 
an association with reduced mortality in these individuals (247). Further, physical 
activity interventions have helped to reduce cardiovascular risk factors, contribute 
to weight loss and improve the well-being in individuals with T2D (248, 249).
Despite the well-known and wide-ranging health benefits of physical activity, 
physical inactivity has become one of the leading public health problems of the 
21st century. According to the WHO, more than 80% of the world’s adolescent 
population is insufficiently active, and inactivity is one of the leading risk factors 
for death worldwide. Physical inactivity caused over 5.3 million deaths, i.e. 9% of 
premature mortality, worldwide in 2008 (250). In addition, prolonged sedentary 
time has raised concerns over the years. A recent study by Diaz et al. showed that 
uninterrupted bouts of sedentary time were associated with all-cause mortality, and 
prolonged sitting has been shown to be a health risk distinguishable from overall 
physical activity (251, 252).
Health-related physical fitness involves different components: cardiovascular 
fitness, musculoskeletal fitness, body composition and metabolism. It refers to a 
physiologic state, and it can be measured more accurately than physical activity, 
which is behavioural. Both physical activity and fitness lead to significant health 
benefits, but evidence suggests that fitness is a more significant predictor of health 
benefits than physical activity. (253, 254) Interestingly, both also have a genetic 
component. First, the body’s responses to physical activity vary among individuals, 
and this is at least partly explained by genetics. Fitness is also influenced by genetics 
(255); for example, VO2max does not increase equally in response to exercise among 
people (256). Therefore, to reach a certain fitness level, an individual might have to 
do significantly more activity than another. Second, twin studies have shown that 
participation in physical activity has a genetic component that is higher for high-
intensity activity than for moderate (257–260, 260). Furthermore, as genetics plays 
a certain role in physical activity and fitness, it also impacts the susceptibility to 
chronic diseases and disease risk factors, and these genes may overlap. Nevertheless, 
genetics is not a target for health interventions, and randomised control trials show 
substantial health benefits of physical activity (7). Furthermore, a study from the 
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Finnish Twin Cohort showed that LTPA is associated with reduced mortality, even 
after adjustment for genetic and other familial factors (261). 
2.4 Physical activity and type 1 diabetes 
2.4.1 Physical activity, hormonal responses and blood glucose in type 1 diabetes
The maintenance of an optimal glucose balance with physical activity requires 
knowledge of the metabolic and hormonal responses related to type 1 diabetes 
and the external administration of insulin. On top of this, a lot of information and 
know-how are required to adjust and optimise insulin doses and food intake with 
alternating metabolic circumstances related to physical activity. The metabolic and 
blood glucose responses to exercise vary depending on the duration, intensity, timing 
and type of the activity (262). Also, other factors contribute to the highly variable 
glucose responses. For example, meal consistency and timing, the site of insulin 
injections, the peak action of insulin, the starting glucose levels, prior exercise or 
hypoglycaemia, stress level, environmental factors such as temperature and altitude, 
individual fitness and menstrual cycle may all alter the glucose response to activity 
(262).   
In non-diabetic subjects, insulin secretion is reduced during prolonged aerobic 
activity, while the glucagon secretion increases. This induces glycogenolysis and 
gluconeogenesis in the liver, which facilitates glucose supply for the working muscles. 
As the duration of physical activity is prolonged, the muscle glycogen stores are 
depleted. Consequently, the glucose output from the liver and an activated lipolysis 
also augmented by other counterregulatory hormones (mainly catecholamines, 
cortisol and growth hormones (GH)) become more important as energy sources. 
(263) In individuals with type 1 diabetes, the physiological reduction in insulin 
secretion is absent, and the amount of circulating insulin depends on the dose 
and timing of the exogenous insulin administration (264). In addition, physical 
activity increases blood flow in the subcutaneous tissue, thereby also increasing the 
absorption of insulin. Typically, without modulation of insulin dosing, prolonged 
activity leads to a progressive decline in blood glucose. This relative excess of insulin 
also affects the utilised fuel sources. Lipolysis may decline, and the muscles will 
therefore be more dependent on glucose. In addition, high relative insulin levels 
lead to decreased glucose disposal from the liver, increased muscle glucose uptake 
and decreased glycogen utilisation. (265) 
On the contrary, if exercise is initiated during insulin deprivation and 
hyperglycaemia, there is a substantial risk that exercise will further elevate the 
glucose levels due to inappropriate counterregulatory responses and fuel metabolism, 
and this may even lead to severe ketosis (264). In addition, aerobic exercise during 
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hyperglycaemia increases the rate of carbohydrate oxidation over lipid oxidation 
compared to exercise during physiological conditions with normal glycaemia. On 
the other hand, during near physiological insulin concentrations and euglycaemic 
conditions, the fuel metabolism is similar between individuals with type 1 diabetes 
and healthy subjects. (266)
Higher-intensity activities increase the proportion of glucose compared to 
lipids as a fuel source (267). Therefore, especially prolonged and intensive exercise 
increases the carbohydrate demand, which must be considered by individuals with 
type 1 diabetes before and during exercise. Generally, guidelines recommend insulin 
dosage reduction before, during and after exercise, and/or extra carbohydrate 
consumption due to increased insulin sensitivity and carbohydrate demand (268). 
On the other hand, in short anaerobic activities, the catecholamines increase blood 
glucose levels, which is accompanied by a quick increase in blood insulin levels in 
healthy individuals (269). Also, in shorter, partly anaerobic high-intensity interval 
sessions, there is less reduction in insulin levels than in prolonged aerobic activities. 
After a high-intensity interval session, insulin levels increase in order to counteract 
changes in metabolites and the increased counterregulatory hormone responses to 
prevent hyperglycaemia. Therefore, an individual with type 1 diabetes might need an 
extra bolus of insulin to prevent hyperglycaemia related to intense activities. (270) 
However, it is important to exercise with caution in order to avoid post-exercise 
hypoglycaemia due to increased insulin sensitivity and replenishment of glycogen 
stores (267). 
The main adverse event related to physical activity in type 1 diabetes is 
hypoglycaemia. In fact, the fear of severe hypoglycaemia is the most significant barrier 
to exercising for many individuals with type 1 diabetes (271). First, the increase in 
post-exercise insulin sensitivity is an important reason that hypoglycaemia lasts up to 
24–48 h following the exercise (263, 265). The risk for hypoglycaemia after physical 
activity is higher for at least 24 hours (263). In addition, studies have shown that the 
normal counterregulatory hormone response may be deficient in individuals with 
type 1 diabetes. Previous hypoglycaemic events impair this response even further, 
resulting in a greater likelihood of further hypoglycaemic events. Interestingly, even 
in healthy individuals, hypoglycaemia diminishes counterregulatory responses to 
exercise. (265) In type 1 diabetes, this antecedent hypoglycaemia-induced autonomic 
failure is a significant mechanism resulting in inadequate endogenous glucose 
production and hypoglycaemia (272). In addition, autonomic neuropathy causes 
hypoglycaemia unawareness, and it further attenuates the sympathetic response 
to hypoglycaemia after previous hypoglycaemia, leading to a potential vicious cycle 
of hypoglycaemic events (273). Moreover, it has been shown that physical activity 
itself may decrease the counterregulatory response to hypoglycaemia (274). 
Physical activity improves glycaemic control (measured by HbA1c) in type 2 
diabetes, and this has been shown in a variety of different forms of exercise, such 
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as aerobic and resistance training (275). However, in type 1 diabetes, the data are 
inconsistent, and there is no clear established benefit. A meta-analysis by Kennedy 
et al. showed no clear benefit of exercise on glycaemia in individuals with type 1 
diabetes. It is however of note, that the data demonstrated that physical activity can 
be undertaken safely without significant hypoglycaemia. (276) This is important 
since physical activity provides significant benefits in type 1 diabetes, in which 
hypoglycaemia is the main barrier to exercising (271). In adolescents, however, it 
seems that physical activity is associated with better glycaemic control. A recent 
meta-analysis of 10 trials in individuals below 18 years of age showed an overall 
significant benefit of physical activity on glycaemic control, measured as HbA1c (277). 
2.4.2 Physical activity and type 1 diabetes: health benefits and  
impacts on complications
The consensus is that physical activity is beneficial for an individual with type 1 
diabetes and is therefore recommended by the guidelines. However, research data 
on the matter are surprisingly limited, especially regarding diabetic complications 
and mortality, not to mention the lack of exercise intervention studies. Most of the 
guidelines are based on knowledge obtained from type 2 diabetes and the general 
population. There is evidence that complication-free and young individuals with type 
1 diabetes are as physically active as their peers (278). As we know, most youth do 
not meet the general recommendations for activity, so these levels are not optimal. 
Adults with type 1 diabetes are less active and have lower fitness levels than their 
non-diabetic peers (271, 278, 279). 
Data on the impact of physical activity on diabetic complications and 
mortality in type 1 diabetes are scarce. However, studies implicate that physical 
activity benefits many risk factors associated with the development of diabetic 
complications and mortality in type 1 diabetes. Several studies have shown 
the benefit of physical activity on the lipid profile by increasing the amount of 
high-density lipoprotein cholesterol and decreasing the low-density lipoprotein 
cholesterol and triacylglycerol levels (280–282). Also, physical activity decreased 
the level of apolipoprotein B (proatherogenic), whereas a polipoprotein A-1 (which 
protects against atherosclerosis) was increased (283, 284). Endothelial dysfunction 
is associated with cardiovascular events and is more common in individuals with 
type 1 diabetes. Studies have shown that physical activity improves endothelial 
function in these individuals (285–287). Regarding hypertension, there are only 
a few studies assessing the association of physical activity with blood pressure in 
individuals with type 1 diabetes, and most of these studies have not shown a clear 
benefit; however, the number of participants in these studies has been relatively 
small (282, 287, 288). In contrast, a study by Lehmann et al. showed a statistically 
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significant reduction in both systolic (SBP) and diastolic blood pressure (DBP) 
after a three-month exercise intervention (289). 
Several studies have shown that physical activity improves fitness in individuals 
with type 1 diabetes (287, 290, 291). Also, physical activity improves well-being: self-
reported physical activity was associated with a better quality of life in individuals 
with type 1 diabetes (292).
Traditionally, type 1 diabetes has been considered a disease of the lean and is 
characterised by an absolute insulin deficiency. However, the prevalence of obesity 
has increased in type 1 diabetes, and insulin resistance is independently associated 
with an increased risk of micro- and macrovascular complications (293–295). In 
addition, insulin resistance may be accompanied by the clustering of other CVD 
and metabolic risk factors, such as elevated blood pressure, worse lipid profile, 
inflammation and visceral fat (296, 297). Several studies have shown that physical 
activity improves insulin sensitivity (281, 287, 291). Moreover, Ramalho et al. 
showed that both aerobic and resistance training improves insulin sensitivity (298). 
Due to the beneficial effects of several risk factors, it can be assumed that 
physical activity might reduce the risk of diabetic micro- and macrovascular 
complications. Previous cross-sectional studies have shown that more physically 
active individuals with type 1 diabetes have fewer signs of diabetic nephropathy, 
neuropathy and retinopathy than less active individuals (299, 300). In addition, 
we previously showed that individuals with type 1 diabetes and microalbuminuria 
reported undertaking physical activity of lower intensity compared with individuals 
without albuminuria (300). The study design was cross-sectional, and the result 
could be due to the fact that complication-free individuals are more likely to engage 
in physical activity, but on the other hand, people with microalbuminuria usually 
have no symptoms and may not be aware of it. 
Prospective data regarding physical activity and its association with diabetic 
complications and mortality are very limited in type 1 diabetes. To our knowledge, no 
studies have assessed the relationship between physical activity and the development 
and progression of renal disease in type 1 diabetes using a prospective study design. 
So far, the strongest evidence regarding physical activity and macrovascular disease 
and mortality derives from the Pittsburgh IDDM Morbidity and Mortality study. 
Men who participated in team sports during high school were less likely to die 
prematurely or to have macrovascular disease after having type 1 diabetes for 25 
years (301). Also, retrospective information on physical activity at 14–17 years of age 
was associated with less neuropathy and nephropathy. However, this was found in 
men only, and physical activity during adolescence was not associated with severe 
retinopathy or blindness (299). Furthermore, these individuals were followed 
during adulthood, and overall physical activity was assessed by a standardised 
questionnaire. The level of physical activity was inversely associated with mortality, 
even after controlling for a number of potential confounders (age, BMI, insulin doses, 
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diabetic complications, smoking, current alcohol consumption). Again, however, 
this association was statistically significant only in men. (278) In addition to the 
Pittsburgh study, the EURODIAB study reported a borderline inverse association 
between physical activity and all-cause mortality when both sexes were combined 
(302). Regarding CVD, a borderline inverse association was found only in women. 
Moreover, the landmark Wisconsin Epidemiologic Study of Diabetic Retinopathy 
(WESDR) showed that participation in high school team sports was associated with 
lower incidence of diabetic retinopathy, but only in a subgroup of women diagnosed 
with diabetes under the age of 14 (303).
2.4.3 Recommendations of physical activity in type 1 diabetes
The recommendations for physical activity and diabetes have recently been updated 
in the ADA position statement for diabetes and physical activity/exercise (268). The 
weekly minimum amount of physical activity recommended for most adults with 
diabetes includes 150 minutes of physical activity with an intensity level of moderate-
to-vigorous. This amount should be divided into at least three different days per 
week, and there should be no more than two consecutive days without physical 
activity. More than 75 minutes of interval training or vigorous activity per week might 
be sufficient for individuals that are more physically fit. In addition, 2–3 resistance 
training sessions should be performed every week in non-consecutive days, and for 
older adults, 2–3 flexibility and balance training sessions are also recommended. 
Additionally, an individual with diabetes should reduce daily sedentary time. Long-
term sitting should be interrupted every 30 minutes with bouts of light activity. 
This does not replace the other recommended amount of weekly physical activity. 
(268) The recommendations for physical activity for type 1 diabetes are very similar 
in the Finnish Current Care guidelines (5).
As discussed earlier, the glucose responses to exercise are affected by many 
factors, and therefore, specific and uniform recommendations for exercise-related 
glycaemic control is not possible. Frequent blood glucose measurements, however, 
are necessary for adjusting the optimal carbohydrate amount and insulin dosing. 
Exercise is not recommended during hyperglycaemia or elevated blood ketones. 
Individualised patient education is crucial for optimising insulin dosages that depend 
on blood glucose levels and the type of physical activity engaged. Specific medical 
clearance before engaging in light to moderate physical activity is usually not needed 
for an asymptomatic patient beyond normal guideline-conducted diabetes care 
(268). However, if an individual with diabetes has complications or is increasing 
the intensity level of physical activity, examination and approval by a physician is 
recommended, and in some cases, an exercise stress test is required before engaging 
in physical activity (5, 268). 
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3 AIMS OF THE STUDY
The data regarding physical activity and diabetic complications and mortality in type 
1 diabetes are limited. The main objective of this study, therefore, was to investigate 
the role of LTPA in the development of diabetic complications and mortality in 
individuals with type 1 diabetes in a prospective study design. 
Specifically, the aims of the present study were: 
I  To examine the relationship between physical activity and the development 
and progression of diabetic nephropathy in individuals with type 1 diabetes.
II  To assess whether physical activity is associated with the risk of incident or 
recurrent CVD events in individuals with type 1 diabetes.
III  To evaluate the association between physical activity and all-cause and CVD 
mortality in individuals with type 1 diabetes with and without CKD.
IV  To investigate the association between physical activity and the development 
of severe diabetic retinopathy in individuals with type 1 diabetes.
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4 SUBJECTS AND STUDY DESIGN
4.1 The FinnDiane Study
The individuals included in these studies are participants of the ongoing nationwide 
and multi-centre Finnish Diabetic Nephropathy (FinnDiane) Study that was 
launched in 1997. The FinnDiane Study aims to identify clinical, biochemical, genetic 
and environmental risk factors for diabetic complications, with an emphasis on 
diabetic nephropathy. So far, over 5000 adult individuals with type 1 diabetes – 
that is, more than 10% of the total number of individuals with type 1 diabetes in 
Finland – have been recruited and thoroughly characterised. The distribution of the 
FinnDiane patients is shown in Figure 2. The study centres include all 5 university 
hospitals, all 16 central hospitals, 26 regional hospitals and 30 primary healthcare 
units (Appendix). 
Figure 2. Geographical distribution of the FinnDiane patients. Each dot indicates one FinnDiane 
patient. The distribution is similar to the distribution of the general Finnish population.
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The LTPA questionnaire was introduced at the beginning of the year 2000, and 
in this thesis, all participants with available data on baseline LTPA were included. 
Until 2011, a total of 62% of the participants in the FinnDiane Study had answered 
the questionnaire. The clinical characteristics of the questionnaire respondents 
were comparable to those that did not participate. None of the participants had 
comprehensive data available for all the different LTPA components, but we aimed 
to use the maximum amount of available data. Therefore, the total number of 
patients differed somewhat in the analyses of total amount, intensity, frequency 
and duration of LTPA. Follow-up data have been collected since 2004. The study 
design of this thesis was prospective and observational. The inclusion criteria for 
the participants in each study is shown in Figure 3. 
Figure 3. Flow chart of patient selections: Studies I–IV.
ESRD: End-stage renal disease, CVD: Cardiovascular disease, UAER: Urinary albumin excretion 
rate, LTPA: Leisure-time physical activity, CKD: Chronic kidney disease.
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4 Subjects and study design
4.2 Study population: clinical characteristics (Studies I–IV)
The inclusion criteria for the study population in each study is shown in the Methods 
section, 4.1 Figure 3. The baseline clinical characteristics of the study population 
in each study are shown in Table 3. 
Table 3. Clinical characteristics of the study population (Studies I–IV)
4.2 Study population: clinical characteristics (Studies I–IV) 
 
The inclusion criteria for the study population in each study is shown in the Methods 
section, 4.1 Figure 3. The baseline clinical characteristics of the study population in 
each study are shown in Table 3.  
 




4.3 Ethical aspects 
 
The study protocol was approved by the ethics committees of all participating centres 
as well as the Ethics Committee of the Helsinki and Uusimaa Health Region. Written 
informed consent was obtained from each patient prior to participation, and the study 
was performed in accordance with the Declaration of Helsinki. 
  
 Study I Study II Study III Study IV 
N 1424 2074 2639 1612 
Male (%) 48.5 47.2 48.5 44.7 
Duration of diabetes (years) 20.4 ± 12.3 21.7 ± 12.4 23.3 ± 12.8 18.9 ± 11.7 
Age (years) 37.0 ± 12.4 38.8 ± 12.4 40.1 ±12.6 37.0 ± 11.9 
BMI  (kg/m2) 25.0 ± 3.4 25.2 ± 3.6 25.2 ± 3.6 25.1 ± 3.6 
SBP (mmHg) 132 ± 16 133 ± 17 135 ± 19 131 ± 16 
HbA1c 8.3 ± 1.4% 
(67 ± 15 
mmol/mol) 
8.3 ± 1.4% 
(67 ± 15 
mmol/mol) 
 
8.3 ± 1.4% 
(67 ± 15 
mmol/mol) 
8.2 ± 1.4% 
(66 ± 15) 
mmol/mol 
Current or previous 
smokers (%) 
42.6 44.4 44.8 41.5 
Normal UAER (%) 75.4 74.9 68.9 87 
Sedentary (%) 29.1 33.2 31.6 29.9 
4.3 Ethical aspects
Th  study proto ol was approved by the ethics committees of ll participating c tres 
as well as the Ethics Committee of the Helsinki and Uusimaa Health Region. Written 
informed consent was obtained from each patient prior to participation, and the 
study was performed in accordance with the Declaration of Helsinki.
45
5 METHODS
5.1 The FinnDiane Study protocol
During a regular visit to the attending physician, data on thorough medical history, 
medication, cardiovascular status and diabetic complications were recorded by 
a standardised questionnaire and completed and verified through the medical 
files. Information on the history of smoking and current alcohol consumption 
was assessed by standardised questionnaires. The regular visits also included 
urine collections, blood samples for laboratory measurements and various assays, 
measurements of anthropometric parameters and blood pressure (121). 
5.1.1 Definition of type 1 diabetes
Type 1 diabetes was defined as the onset of diabetes before the age of 35 (Study 
I) or 40 years (Studies II–IV) and with insulin treatment initiated within 1 year 
of diagnosis.
5.1.2 Definition of diabetic nephropathy and assessment of renal function
Renal status was categorised based on local and central measurements UAER 
in either a timed overnight or 24-h urine collection in at least two out of three 
consecutive measurements. Renal status was categorised as follows: normal UAER 
<20 μg/min or <30 mg/24 h; microalbuminuria ≥20 and <200 μg/min or ≥30 and 
<300 mg/24 h (n=295); or macroalbuminuria ≥200 μg/min or ≥300 mg/24 h. 
Participants requiring dialysis or having received a kidney transplant were classified 
as having end-stage renal disease (ESRD). Diabetic nephropathy was defined as 
macroalbuminuria or ESRD. Individuals with unknown renal status were excluded. 
We assessed the progression of diabetic nephropathy during follow-up in Study I, 
and renal progression was defined as any shift to a higher albuminuria class or the 
development of ESRD. Renal function (estimated glomerular filtration rate [eGFR]) 
was estimated using the Chronic Kidney Disease Epidemiology Collaboration 
equation (CKD-EPI) (66). In Study III, individuals with eGFR ≤60 mL/min/1.73 
m2 or ESRD were classified as having CKD. However, individuals with a kidney 
transplant and eGFR >60 mL/min/1.73 m2 (n=53) were not defined as having 
CKD. In addition, patients with CKD were classified as having CKD without ESRD, 
undergoing dialysis or having a kidney transplant (Study III). 
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5 Methods
5.1.3 Definition of CVD 
In study I, CVD was defined as a clinically verified myocardial infarction, coronary 
revascularisation procedure, stroke, ischaemic limb amputation or a peripheral 
artery revascularisation procedure. In Studies II–IV, a major CVD event was defined 
as a clinically verified myocardial infarction (ICD-8/9 410–412, ICD-10 I21–I23), 
coronary procedure (bypass grafting surgery or angioplasty based on the Nordic 
Classifications of Surgical Procedures) or either an ischaemic or haemorrhagic stroke 
(ICD-8/9 430–434, ICD-10 I60–I64). Follow-up events of CVD were identified 
from the Care Register for Health Care (HILMO) and the Finnish Causes of Death 
Registry and were verified with medical records. The date of the first CVD event 
was defined as the date of hospital admission due to CVD. 
5.1.4 Definition of severe diabetic retinopathy
Severe diabetic retinopathy is defined as the initiation of laser treatment due to severe 
non-proliferative retinopathy, proliferative retinopathy or diabetic maculopathy, as 
identified by the Care Register for Health Care (HILMO). 
5.1.5 Anthropometric measurements
Anthropometric data were collected by a trained nurse. Body weight was registered 
to the closest 0.1 kg, and height was registered to the closest 1 cm. The calculation 
of weight-to-hip ratio (WHR) included dividing the waist circumference (measured 
midway between the lowest ribs and the iliac crest) by the hip circumference 
(measured at the major trochanters of the femurs). Body mass index (BMI) was 
calculated as body weight/height2 (kg/m2). Blood pressure was measured twice after 
a 10-minute rest with a 2-minute interval either by a manual sphygmomanometer 
or an automated blood pressure measurement device. The mean values of SBP and 
DBP were calculated and used in the analyses. 
5.1.6 Definition of smoking
Data on smoking status were collected by a self-administered questionnaire. 
Participants were categorised either as current smokers, previous smokers or never 
smokers. History of smoking was defined as smoking one or more cigarettes per 
day for at least 3 months and ceasing prior to data collection. Current smoking was 
defined as smoking at least one cigarette a day during data collection.
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5.1.7 Laboratory measurements and assays
Blood samples were drawn to analyse the lipid profile, HbA
1c
 and creatinine. Serum 
lipids and lipoproteins were measured at the research laboratory of Professor 
Marja-Riitta Taskinen, Department of Medicine, Division of Cardiology, Helsinki 
University Hospital, Helsinki, Finland. The Friedewald formula was used to calculate 
LDL cholesterol (304). The measurement of serum creatinine was performed by 
a kinetic Jaffé reaction until January 2002 and afterwards by a photometric, 
enzymatic method (Hitachi 917 or Modular analyser, Boehringer Mannheim/
Roche Diagnostics, Basel, Switzerland). HbA
1c
 was measured locally at each study 
centre by standardised assays with a normal range of 20–42 mmol/mol (4.0–6.0%). 
Urinary albumin concentration was measured with RIA until 1 November, 2002, 
and thereafter by immunoturbidimetry.
5.2 Assessment of physical activity
LTPA was assessed by a baseline self-report questionnaire, introduced at the 
beginning of 2000, and in this study, we included all individuals with available data 
on LTPA. The “KIHD 12-month Leisure-Time Physical Activity Questionnaire” is a 
Finnish conversion of the Minnesota Leisure-Time Activity Questionnaire that was 
validated against double-labelled water (305, 306). The KIHD questionnaire has 
been validated in 1163 Finnish men from the general population, with maximum 
oxygen uptake as the standard method validation (307). 
The questionnaire is a detailed quantitative questionnaire assessing duration, 
frequency and mean intensity of the most common lifestyle and structured LTPA 
in Finland, as recalled over the previous 12 months. The first section of the 
questionnaire contains questions of general type, frequency, duration and intensity 
of LTPA. Information about general activity duration, frequency and intensity was 
used from the first section of the questionnaire. Additionally, a second section asks 
specific details on frequency (times per month), duration per session and intensity 
for 21 types of predefined activities retrospectively from the past 12 months. Based 
on the intensity level (0–3), each of the 21 activities is assigned a specific metabolic 
equivalent (MET) value. In addition, the questionnaire contains a third section that 
assesses physical activity at work. However, the amount of data in this section was 
limited and was therefore not used in the analyses in this thesis. 
The studies considering this questionnaire imply that it is representative and 
shows relatively small intra-person variability, and the 12-month LTPA correlated 
with the VO2max (308). The classification of the sedentary level of LTPA (<10 METh/
week) was defined as an LTPA lower than the minimum given by general physical 
activity guidelines (309). For the moderately active and active threshold levels, 
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we used an arbitrary cut-off, which we have used in our previous publications 
(moderately active 10–40 METh/week and active >40 METh/ week) (300, 310). 
We also analysed other LTPA-related exposures: (1) exercise intensity (low: no 
self-reported subjective shortness of breath and no sweating, moderate: a moderate 
degree of self-reported subjective shortness of breath and sweating, and high: a high 
degree of subjective shortness of breath and sweating); (2) single session duration 
(low: ≤30, moderate: 31–60 and high: >60 min/session); and (3) exercise frequency 
(low: <1, moderate: 1–2, and high: >2 sessions/week). The classification of LTPA 
and its components are shown in Table 4. 
Table 4. Classification of LTPA and its components
validated in 1163 Finnish men from the general population, with maximum oxygen 
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from the first section of the questionnaire. Additionally, a second section asks specific 
details on frequency (times per month), duration per session and intensity for 21 types 
of predefined activities retrospectively from the past 12 months. Based on the 
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a high degree of 
subjective shortness of 






The statistical analyses were performed with SPSS Statistics versions 21 and 22.2 
(IBM, Armonk, NY, USA) and SAS version 9.3 (SAS Institute, Cary, NC), and the 
figures were drawn using GraphPad Prism version 5 (GraphPad, La Jolla, CA, 
USA). Data are presented as means ± SD if normally distributed and otherwise as 
median and interquartile range (IQR). Categorical variables are given as percentages. 
ANOVA was used for normally distributed variables, and the Kruskal–Wallis test 
was used for non-normally distributed variables. For categorical variables, the χ2 
test was used. Trend test p-values were used when appropriate. The cumulative 
incidence or progression rates were estimated using the Kaplan–Meier method, 
and the log rank test was used to test between-group differences. Follow-up started 
from the baseline visit (2000–2013). The person-years at risk were calculated until 
the progression of renal status, death or the end of 2012 (Study I); the first CVD 
event, death or the end of 2013 (Study II); death or the end of 2014 (Study III); 
the first severe diabetic retinopathy event, death or the end of 2015 (Study IV). 
The association between different LTPA components and the different end points 
(renal progression, incident CVD event, death or first severe diabetic retinopathy 
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event) were analysed using univariable and multivariable Cox proportional hazards 
regression models. The highest category for each LTPA component was used as a 
reference group in all multivariable analyses, and the results are presented as HRs 
with 95% CIs. A p-value of <0.05 was considered statistically significant.
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6 RESULTS
6.1 Study I: The association of LTPA with the development and 
progression of diabetic nephropathy in type 1 diabetes
In this study, we assessed how LTPA is associated with the development and 
progression of diabetic nephropathy in individuals with type 1 diabetes. At baseline, 
physically inactive participants had more often a history of smoking, and they 
consumed more alcohol and were on antihypertensive drugs more frequently. In 
addition, individuals with a lower level of LTPA had more abdominal obesity, worse 
glycaemic control and a higher triacylglycerol level. LTPA was not associated with 
gender, age or duration of diabetes.
During a follow-up time of 6.4 ± 3.1 years, 149 individuals progressed 
in their renal status. A total of 72 normoalbuminuric individuals developed 
microalbuminuria, 35 microalbuminuric individuals developed macroalbuminuria, 
and 42 macroalbuminuric individuals developed ESRD. At baseline, the subjects 
that progressed in their renal status were heavier and had higher blood pressure, 
worse glycaemic control and lipid profile. In addition, progressors were primarily 
male, previous or current smokers, and they consumed more alcohol. 
Figure 4 presents the Kaplan–Meier curves showing the relationship between 
LTPA and its components with renal progression. The intensity and frequency 
of LTPA were associated with the progression of renal status: in patients with a 
low intensity of LTPA, the 10-year cumulative progression rate was 24.0% (95% 
CI 18.8, 28.8); in those with a moderate intensity of LTPA, it was 13.5% (95% CI 
10.3,16.6); and in those with a high intensity of LTPA 13.1% (95% CI 10.3, 16.6) 
(p=0.01). Also, participants with an LTPA frequency of <1, 1–2 or >2 times per 
week had a 10-year cumulative risk of progression of renal status of 24.7% (95% 
CI 18.3, 30.7), 14.7% (95% CI 10.2, 19.0) or 12.6% (95% CI 9.4, 15.7), respectively 
(p=0.003). The total amount of LTPA and single-session duration, however, were 








Figure 4. Kaplan–Meier curves for total LTPA and components of LTPA regarding progression 
of renal status, defined as any shift to a higher albuminuria class or to ESRD.  
Adapted by permission from Springer Nature, Diabetologia 2015;58(5):929–936. 
Copyright © 2015, Springer Nature
Table 4 presents the multivariable analyses of the association of low vs. moderate 
and high LTPA intensity with progression of renal status. Model 1 is a univariable 
model including the intensity of LTPA. In model 2, we added static confounders, 
such as duration of diabetes, sex and current smoking. At this stage, the intensity 
of LTPA was still associated with renal progression. In contrast, in models 3–6, 
the confounding factors (HbA1c, BP, triacylglycerol and BMI) that could potentially 
be influenced by physical activity incrementally decreased this association to a 
non-significant level. The association with LTPA frequency and renal progression 
decreased to a non-significant level after adjusting for either static or dynamic 
confounders. 
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Table 4. Cox regression models showing hazard ratios for low vs. moderate and high intensity 
LTPA for progression of renal status 
progression of renal status, defined as any shift to a higher albuminuria class or to 
ESRD.   
 
Adapted by permission from Springer Nature, Diabetologia 2015;58(5):929-936. 
Copyright © 2015, Springer Nature 
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including the intensity of LTPA. In model 2, we added static confounders, such as 
duration of diabetes, sex and current smoking. At this stage, the intensity of LTPA 
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 HR (95% CI)  HR (95% CI)  HR (95% CI)  
Model 1 n=1230 
1.79 (1.19, 2.69) 
n=1049 
1.54 (0.92, 2.59) 
n=160 
1.17 (0.63, 2.17) 
Model 2 n=1211 
1.58 (1.04, 2.41) 
n=1035 
1.41 (0.83, 2.41) 
n=159 
1.20 (0.64, 2.27) 
Model 3 n=1198 
1.53 (1.00, 2.32) 
n=1024 
1.31 (0.77, 2.23) 
n=154 
1.23 (0.62, 2.46) 
Model 4 n=1190 
1.46 (0.96, 2.24) 
n=1016 
1.26 (0.73, 2.17) 
n=153 
1.28 (0.64, 2.56) 
Model 5 n=1160 
1.43 (0.93, 2.22) 
n=989 
1.31 (0.76, 2.27) 
n=147 
1.36 (0.67, 2.79) 
Model 6 n=1156 
1.48 (0.96, 2.29) 
n=986 
1.22 (0.70, 2.14) 
n=147 
1.40 (0.67, 2.94) 
 
Model 1: low-intensity LTPA 
Model 2: Model 1 + sex, duration of diabetes and current smoking 
Model 3: Model 2 + HbA1c 
Model 4: Model 2 + mean arterial pressure 
Model 5: Model 2 + triacylglycerol 
Model 6: Model 2 + BMI  
 
LTPA: leisure-time physical activity. 
 
Adapted by permission from Springer Nature, Diabetologia 2015;58:929-936. 
Copyright © 2015, Springer Nature 
  
To assess the possible bias regarding baseline renal disease and physical inactivity, 
we separately analysed the association of LTPA and its components with the 
Model 1: low-intensit  TPA
Model 2: Model 1 + s , ti n of diab tes and current smoking
Model 3: Model  1c
Model 4: odel an arterial pressure
Model 5: Model  i l l erol
Model 6: Model I 
LTPA: leisure-time ph si l ti it .
Adapted by permission from Springer Nature, Diabetologia 2015;58:929-936.
Copyright © 2015, Springer Nature
To assess the possible bias regarding baseline renal disease and physical inactivity, we 
separately analysed the association of LTPA and its components with the development 
of de novo microalbuminuria (shift from normo- to microalbuminuria). In the 
Kaplan–Meier models, only LTPA intensity was associated with the development 
of microalbuminuria: the cumulative progression rate in an 8-year follow-up was 
15.4% (95% CI 9.4, 21.0), 6.9% (95% CI 4.5, 9.3) and 5.9% (95% CI 2.1, 9.6) in the 
low-, moderate- and high-intensity groups, respectively (p=0.047, log rank test). 
Regarding intensity in this sub-analysis, the finding in the multivariable analyses 
showed comparable HRs but non-significant p-values after correction for both static 
and dynamic confounders. For total LTPA, the development of microalbuminuria 
was significantly higher in sedentary individuals compared with those with 
moderately active or active levels of LTPA, at 1.90 (95% CI 1.04, 3.49) in the final 
Cox regression model. LTPA frequency or duration showed no association with the 
development of microalbuminuria in either the univariable or multivariable models. 
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6 Results
6.2 Study II: The association of LTPA with the development of 
incident and recurrent CVD events in type 1 diabetes
We made separate analyses for the association of LTPA and its components with 
the development of an incident and a recurrent CVD event. Of the 2074 individuals 
without a previous CVD event, 206 (9.9%) had an incident CVD event during a 
mean follow-up of 10.3±3.4 years. The Kaplan–Meier curves of the association of 
LTPA and its components with incident CVD are shown in Figure 5. The various 
components were associated with the development of a first major CVD event: the 
10-year cumulative incidence of CVD increased with decreasing amounts of physical 
activity irrespective of which component was studied. Total LTPA (p=0.028), 
exercise intensity (p<0.001), exercise duration (p=0.014) and exercise frequency 






Figure 5. Kaplan–Meier survival analysis for an incident CVD event stratified by total LTPA and 
components of LTPA. LTPA: Leisure-time physical activity. 
Next, we performed the Cox regression analyses. The first model included only 
the physical activity components. In model 2, we added the static confounders 
(duration of diabetes, age at onset of diabetes, diabetic nephropathy and gender) 
to the multivariable analysis. The total amount of LTPA, intensity and frequency 
were still associated with incident CVD. However, the association with duration 
decreased to a non-significant level. The final model 7 included all the static and 
dynamic confounders (triacylglycerol, BMI, SBP, HbA
1c
 and smoking). Only the 
association with frequency remained significant in the final model. The effect of 
LTPA intensity was slightly reduced to become non-significant in model 6, while the 
total amount of LTPA and duration were non-significant in the models including 
dynamic confounders. The Cox regression models are shown in Table 5. 
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6 Results
Table 5. Cox regression models showing hazard ratios for low and moderate vs. high LTPA, 
intensity, frequency and duration for an incident CVD event
Table 5. Cox regression models showing hazard ratios for low and moderate vs. high 
LTPA, intensity, frequency and duration for an incident CVD event 
 LTPA Intensity Frequency Duration 
Model 1:  
     High       
     Moderate 
     Low 
n=2074, 206 events 
1.00 
1.41 (0.92, 2.14) 
1.77 (1.15, 2.72)  
n=2030, 199 events 
1.00 
2.58 (1.55, 4.31) 
4.51 (2.67, 7.63)  
n=2055, 206 events 
1.00 
1.17 (0.69, 2.00) 
1.91 (1.37, 2.64) 
n=2074, 206 events 
1.00 
1.27 (0.91, 1.78) 
1.76 (1.20, 2.60) 
Model 2: 
     High 
     Moderate 
     Low 
n=2074, 206 events  
1.00 
1.51 (0.99, 2.30) 
1.59 (1.03, 2.44) 
n=2030, 199 events 
1.00 
1.49 (0.88, 2.53) 
1.91 (1.11, 3.28) 
n=2055, 206 events 
1.00 
1.56 (0.91, 2.66) 
1.94 (1.39, 2.71) 
n=2074, 206 events 
1.00 
1.17 (0.84, 1.64) 
1.37 (0.93, 2.02) 
Model 3: 
     High 
     Moderate 
     Low 
n=2071, 206 events 
1.00 
1.50 (0.98, 2.28) 
1.51 (0.98, 2.33) 
n=2027, 199 events 
1.00 
1.45 (0.86, 2.45) 
1.77 (1.03, 3.07) 
n=2052, 206 events 
1.00 
1.52 (0.89, 2.61) 
1.84 (1.31, 2.59) 
n=2071, 206 events 
1.00 
1.16 (0.83, 1.63) 
1.29 (0.87, 2.91) 
Model 4: 
     High 
     Moderate 
     Low 
n=2062, 206 events  
1.00 
1.50 (0.98, 2.28) 
1.51 (0.98, 2.33) 
n=2018, 199 events  
1.00 
1.46 (0.86, 2.47) 
1.81 (1.04, 3.12) 
n=2043, 206 events  
1.00 
1.52 (0.89, 2.61) 
1.85 (1.32, 2.60) 
n=2062, 206 events  
1.00 
1.16 (0.83, 1.63) 
1.30 (0.87, 1.92) 
Model 5: 
     High 
     Moderate 
     Low 
n=2052, 206 events  
1.00 
1.50 (0.98, 2.28) 
1.49 (0.97, 2.31) 
n=2008, 199 events  
1.00 
1.47 (0.87, 2.50) 
1.83 (1.06, 3.17) 
n=2033, 206 events  
1.00 
1.48 (0.87, 2.54) 
1.78 (1.27, 2.51) 
n=2052, 206 events  
1.00 
1.21 (0.86, 1.69) 
1.30 (0.87, 1.92) 
Model 6: 
     High 
     Moderate 
     Low 
n=2014, 205 events  
1.00 
1.42 (0.93, 2.17) 
1.38 (0.89, 2.13) 
n=1971, 198 events  
1.00 
1.41 (0.83, 2.40) 
1.68 (0.97, 2.92) 
n=1995, 205 events  
1.00 
1.41 (0.82, 2.42) 
1.66 (1.18, 2.34) 
n=2014, 205 events  
1.00 
1.20 (0.86, 1.69) 
1.26 (0.85, 1.87) 
Model 7: 
     High 
     Moderate 
     Low 
n=1944, 200 events 
1.00 
1.36 (0.89, 2.08) 
1.32 (0.85, 2.04) 
n=1901, 193 events 
1.00 
1.32 (0.78, 2.23) 
1.53 (0.88, 2.68) 
n=1925, 200 events 
1.00 
1.44 (0.84, 2.46) 
1.69 (1.18, 2.42) 
n=1944, 200 events 
1.00 
1.22 (0.87, 1.72) 
1.25 (0.84, 1.86) 
 
Model 1: univariable analysis including the LTPA component and incident CVD 
Model 2: Model 1 + sex, duration of diabetes, age at onset of diabetes and diabetic 
nephropathy 
Model 3: Model 2 + triacylglycerol 
Model 4: Model 3 + BMI 
Model 5: Model 4 + systolic blood pressure  
Model 6: Model 5 + HbA1c 
Model 7: Model 6 + history of smoking 
 
LTPA: leisure-time physical activity.  
 
Adapted by permission from Springer Nature, Diabetologia 2017;60:574-580 Copyright © 2016, 
Springer Nature  
 
We assessed a small group of individuals with a previous CVD event at baseline 
(n=106), the association of LTPA and its components with the recurrence-free time of 
a new CVD event. Of these individuals, 56 had a CVD event during follow-up. Only 
LTPA intensity was associated with the recurrence-free time (p=0.015). The 10-year 
Model 1: univariable analysis including the LTPA component and incident CVD
Model 2: Model 1 + sex, duration of diabetes, age at onset of diabetes and diabetic 
nephropathy
Model 3: Model 2 + triacylglycerol
Model 4: Model 3 + BMI
Model 5: Model 4 + systolic blood pressure 
Model 6: Model 5 + HbA1c
Model 7: Model 6 + history of smoking
LTPA: leisure-time physical activity. 
Adapted by ermission fr m Springer ture, Diabetologia 2 1 ;60:574-580 Copyright © 
2016, Springer Nature 
We assessed a small group of in i i uals with  previous CVD event at baseline 
(n=106), the association of LTPA and its components with the recurrence-free time 
of a new CVD event. Of these individuals, 56 had a CVD event during follow-up. 
Only LTPA intensity was associated with the recurrence-free time (p=0.015). The 
10-year cumulative risk of a recurrent CVD event was 68.5% (95% CI, 63.4, 72.9) 
in the low-intensity group and 45% (95% CI 36.3, 52.5) in the moderate-intensity 
group, while in the high-intensity group (n=2), there were no events during follow-
up. The finding regarding CVD was still statistically significant (HR 1.81 [95% CI 1.04, 
3.16]) when adjusted for the static risk factors (gender, diabetic nephropathy, age 
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at onset of diabetes and duration of diabetes). The association decreased to a non-
significant level when the dynamic confounders were added to the Cox regression 
model (HbA
1c
, systolic BP, smoking, triacylglycerol and BMI).
6.3 Study III: The association of LTPA with premature mortality 
in patients with type 1 diabetes with and without kidney 
disease
We also assessed how baseline LTPA and its components are associated with all-
cause and cardiovascular mortality in individuals with type 1 diabetes in the whole 
study cohort and separately in individuals with and without CKD. 
The study population included 2369 participants, and 310 of them had CKD at 
baseline. During a mean follow-up time of 11.4 ± 3.5 years, 270 participants died 
from any cause. Of these, 75 (27.8%) were cardiovascular deaths. The baseline 
clinical characteristics associated with mortality were history of smoking, male 
gender, higher BMI, age and SBP, longer duration of diabetes, more frequent use 
of antihypertensive drugs, worse lipid profile and worse glycemic control. The 
individuals who died were sedentary more often. The baseline risk factors for a 
cardiovascular death were identical, apart from the history of smoking.  
A higher level of LTPA and all its components (intensity, frequency and 
duration) was associated with the 10-year cumulative rates for all-cause (p<0.001) 
and cardiovascular death (LTPA: p=0.001, intensity: p<0.001, frequency: p=0.01, 
duration p=0.02). The Kaplan–Meier curves for LTPA, its components and all-cause 







Figure 6. Kaplan–Meier survival analysis for all-cause mortality stratified by total LTPA and 
its components. LTPA: Leisure-time physical activity.
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Next, we assessed the association of all-cause and cardiovascular mortality with 
LTPA and its components in a layered Cox regression model. The Cox regression 
models regarding all-cause mortality are shown in Table 6. Model 1 is a univariable 
model that includes the different LTPA components and all-cause mortality. In 
model 2, we added information about smoking and the static confounders (gender, 
diabetic nephropathy, duration of diabetes and age at onset of diabetes). In model 
3, we added the dynamic confounders (those that could be affected by exercise): 
SBP, triglycerides, BMI and HbA
1c
. Both the total amount of LTPA and all the 
LTPA components were still associated with all-cause mortality in the final model 
3, including both smoking and the static and dynamic confounders. Regarding 
cardiovascular mortality, the frequency and intensity of LTPA were associated with 
cardiovascular mortality after adjusting for the static confounders and history of 
smoking (model 2). However, only the association with cardiovascular mortality 
and LTPA intensity remained significant after the final adjustment for all potential 
confounders (model 3).
Table 6. Cox regression models showing hazard ratios for low and moderate vs. high total 
LTPA, intensity, frequency and duration for all-cause mortality 
Table 6. Cox regression models showing hazard ratios for low and moderate vs. high 
total LTPA, intensity, frequency and duration for all-cause mortality  
 
 LTPA Intensity Frequency Duration 




n=2369, 270 events  
1.00  
1.11 (0.75–1.64) 
2.49 (1.71–3.62)  
n=2314, 257 events  
1.00 
2.55 (1.48–4.39)  
7.83 (4.60–13.33)  
n=2346, 264 events  
1.00  
1.13 (0.68–1.89) 
2.92 (2.25–3.79)  
n=2175, 224 events  
1.00 
1.08 (0.79–1.48) 
2.50 (1.75–3.57)  








n=2261, 249 events  
1.00 
1.42 (0.80–2.50) 
2.78 (1.57–4.90)  
n=2292, 255 events  
1.00 
1.45 (0.86–2.43) 
2.35 (1.79–3.09)  
n=2126, 217 events  
1.00 
1.01 (0.73–1.39) 
1.86 (1.29–2.68)  




n=2274, 255 events  
1.00 
1.37 (0.91–2.07) 
1.92 (1.29–2.86)  
n=2221, 244 events  
1.00  
1.34 (0.76–2.38) 
2.39 (1.34–4.25)  
n=2251, 249 events  
1.00  
1.33 (0.79–2.24) 
2.03 (1.53–2.70)  






Model 1: univariable analysis including the LTPA component and all-cause mortality 
Model 2: Model 1 + gender, duration of diabetes, smoking, age at onset of diabetes 
and diabetic nephropathy 
Model 3: Model 2 + systolic blood pressure, triacylglycerol, BMI and HbA1c 
  
LTPA: leisure-time physical activity. 
 
Copyright © 2017 American Diabetes Association From Diabetes Care® 2017;40: 1727-1732. 
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Of the participants with CKD (n=310), 64 had received a kidney transplant, and 36 
were undergoing dialysis. During follow-up, 127 deaths occurred from any cause. 
Both the total amount of LTPA and its components were associated with all-cause 
mortality in the univariable model 1, and this association remained significant in 
model 2 when adjusting for the static risk factors and history of smoking. However, 
only the total amount of LTPA (HR 1.47, 95% CI 1.02–2.12) and LTPA frequency 
(HR 1.90, 95% CI 1.26–2.87) were independently associated with all-cause mortality 
in the final model 3, including the dynamic confounders. The findings in the same 
Cox regression analyses in the participants without CKD were similar to the whole 
study cohort of individuals with type 1 diabetes: the total amount of LTPA and all 
the LTPA components were associated with all-cause mortality when adjusting for 
all the previous confounders (model 3).
6.4 Study IV: The association of LTPA with the development of 
severe diabetic retinopathy in type 1 diabetes 
Of the 1612 individuals with type 1 diabetes, 261 developed severe diabetic 
retinopathy during a mean follow-up time of 10.7 ± 4.6 years. At baseline, those 
that developed severe retinopathy were younger, had higher blood pressure and 
BMI, worse lipid profile, higher HbA1c, more often a history of smoking and more 
frequent use of antihypertensive drugs.
Only a higher frequency of LTPA was associated with a lower 10-year cumulative 
incidence rate of severe diabetic retinopathy during follow-up, as shown in the 






Figure 7. Kaplan–Meier survival analysis for the development of severe diabetic retinopathy 
stratified by total LTPA and components of LTPA. LTPA: Leisure-time physical activity.
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The finding remained significant after adjusting for gender, duration and age at 
onset of diabetes, kidney function (eGFR), BMI, triglycerides and SBP (p=0.045). 
When HbA1c and smoking were added to the Cox regression model, the association 
decreased to a non-significant level. The total amount of LTPA or its components 
(intensity or the duration of a single session) were not associated with severe diabetic 
retinopathy. The Cox regression models regarding the total amount of LTPA and 
all the components are shown in Table 7.
Table 7. Cox regression models showing hazard ratios regarding severe diabetic retinopathy 
for low and moderate vs. high total LTPA, intensity, frequency and duration
 Table 7. Cox regression models showing hazard ratios regarding severe diabetic 
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7 DISCUSSION
7.1 LTPA and the development and progression of diabetic 
nephropathy in type 1 diabetes
In these prospective studies, a higher intensity and frequency of LTPA were 
associated with a slower progression of diabetic nephropathy. To our knowledge, 
there have been no other prospective epidemiological data assessing the association 
of physical activity and the development of diabetic nephropathy in individuals with 
type 1 diabetes. Also, regarding type 2 diabetes, there is no evidence that physical 
activity affects the risk of the development of diabetic kidney disease. 
An alternative explanation for our findings could be that the presence of pre-
existing diabetic nephropathy or other diabetic complications would impair the 
ability to be physically active. For example, exercise intolerance is more common 
in diabetes, and this might contribute to poor exercise adherence (311, 312). The 
presence of macrovascular disease and decreased cardiac performance are evident 
limitations to performing exercise (313). Muscle oxygen supply and utilisation 
may be impaired due to vascular dysfunction and peripheral ischaemia (314). In 
addition, autonomic neuropathy is associated with exercise intolerance possibly 
by causing abnormal haemodynamic responses (315), and diabetic foot ulcers may 
limit the possibility to perform specific types of exercise. The presence of diabetic 
nephropathy itself is associated with reduced physical activity levels, decreased 
physical performance and diabetic complications (316–318). 
To partly address this issue of reverse causality with pre-existing baseline 
renal disease and inactivity, we separately analysed the development of de novo 
microalbuminuria. In these individuals, a lower intensity of LTPA was associated 
with a more rapid initial progression rate during the 8-year follow-up. However, the 
differences regarding the progression from normo- to microalbuminuria flattened 
out during the further follow-up period. Importantly, we demonstrated in another 
study that our FinnDiane individuals with type 1 diabetes and normoalbuminuria 
otherwise seem to be of good health despite their diabetes because their mortality 
was not different from that of the age- and gender-matched non-diabetic Finnish 
population, which would indicate a low occurrence, for instance, of undiagnosed 
cardiovascular morbidity, which would reduce exercise tolerance (6). 
Our finding regarding the potential importance of physical activity intensity is 
interesting, and with this finding, we extend our previous cross-sectional results 
(300). Continuous moderate aerobic exercise has established health benefits and 
is prescribed in most exercise programs. Interestingly, a number of findings during 
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recent years show that intensive exercise might provide additional health benefits 
and may involve distinct mechanisms other than just higher energy consumption. 
High-intensity interval training has shown greater benefits for improving endothelial 
function, markers of sympathetic activity, arterial stiffness, insulin sensitivity, blood 
glucose and lipids compared to continuous moderate-intensity exercise training 
(319, 320). For example, just three minutes of intensive exercise per week improved 
insulin action (321), and intensive training of short duration improved glycaemia in 
individuals with type 2 diabetes (322). Life expectancy was longer with vigorous than 
with non-vigorous exercise (323, 324). The intensity of LTPA was more important 
than the total energy output in the association of hypertension and premature 
mortality (325). LTPA intensity was also associated with reduced risk of CHD (326), 
as well as reduced levels of subcutaneous fat and WHR (327), independent of the 
total energy expenditure of LTPA.
The mechanisms of how LTPA may prevent the development of diabetic 
complications might involve beneficial effects on BP, endothelial function, 
inflammation, sympathetic load, lipid levels, obesity, glycaemic control and 
variability and insulin sensitivity. In line with this view, in our multivariable analyses, 
HbA1c, BP and BMI eliminated the association between LTPA and the progression 
of renal disease, indicating that these confounders might act at least partially as 
intermediate variables in the potential protective pathway of LTPA and renal disease. 
7.2 LTPA and the risk of premature mortality in individuals with 
CKD and type 1 diabetes
In Study III, we separately analysed the association of LTPA and premature death 
in individuals with CKD. Our data show that physical activity is associated with a 
lower risk of premature mortality in individuals with type 1 diabetes and CKD. All 
LTPA components were associated with premature mortality when adjusted for the 
static confounders. However, in the final Cox regression model, including both the 
static and dynamic confounders, only the total amount of LTPA and frequency of 
LTPA were associated with premature mortality in these individuals. 
To our knowledge, the findings regarding premature mortality are novel. 
So far, the impact of physical activity on mortality, cardiovascular outcomes or 
hospitalisation in individuals with CKD is unknown. Previous data show that 
individuals with CKD are physically inactive and have a lower fitness level and 
impaired muscle function (316, 328). It appears that physical activity benefits the 
individuals with CKD: a number of studies show that physical activity is associated 
with improvements in cardiovascular risk factors in this group of individuals (316, 
328). Importantly, physical activity appears to be safe (328). Higher physical 
activity levels were associated with slower decline in kidney function in those 
65
with CKD during follow-up (329), and no studies have reported a worsening of 
the kidney function as a result of exercise. Daily 30-minute bouts of moderate-
intensity exercise are therefore recommended (316). Our findings are in line with 
the current recommendations for physical activity in individuals with CKD. Also, 
these observations were not unexpected given our findings in Study I. 
7.3 LTPA and the incidence of CVD events and the risk of 
premature all-cause and cardiovascular death in type 1 
diabetes
In these studies, we showed in a prospective setting that higher LTPA, in particular 
its frequency and intensity, is associated with a decreased risk of incident CVD 
events in individuals with type 1 diabetes. In addition, the intensity of the LTPA 
was associated with recurrent CVD events when adjusted for the static confounders. 
The intensity of LTPA was associated with cardiovascular mortality when adjusted 
for many potential confounders. All the LTPA components were associated with 
all-cause mortality, even in the final multivariable model. 
Our findings regarding the association of LTPA intensity with recurrent CVD 
events and CVD mortality are in line and confirm our previous findings: LTPA 
intensity was associated with the progression of diabetic nephropathy, and lower 
intensity was associated with prevalent CVD in a cross-sectional setting. Interestingly, 
exercise frequency (>2 sessions/week) most strongly associated with the risk of 
incident CVD. These findings are in line with the current ADA recommendations 
for diabetes, which include moderate to vigorous aerobic exercise for a minimum 
of 150 min/week (spreading the activity over at least 3 days weekly) or for 30 min 
at least 5 days a week. The ADA also recommends going no more than 2 days 
without exercise. (268)
Our observations are in line with and extend the previous limited data on 
physical activity, CVD events and mortality. In the Pittsburgh Insulin-Dependent 
Diabetes Mellitus Morbidity and Mortality study, an inverse association between 
physical activity and mortality and a weak inverse association between participation 
in sports during high school and prevalent CVD was observed, but only in men 
(330). Recently, the EURODIAB study reported a marginally inverse association 
between physical activity and all-cause mortality in both sexes and a borderline 
inverse association between physical activity and incident CVD in women only 
(302). In these studies, however, only the total amount of physical activity was 
analysed, which may explain why the beneficial effects of physical activity on CVD 
and mortality were not found in both sexes or why the association was only of 
borderline significance. Our results show that LTPA is associated with CVD events 
and mortality in both genders. We also repeated the multivariable analyses for men 
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and women separately with respect to LTPA and all the components and all-cause 
mortality. In the final Cox regression model, both the total amount of LTPA and all 
the exercise components (frequency, duration and intensity) were associated with 
all-cause mortality in men. In women, on the other hand, only exercise frequency and 
duration were associated with all-cause mortality in the final model. However, we 
believe that gender-specific differences regarding the association of physical activity 
and mortality are unlikely based on previous studies and these current findings. 
Contrary to the Cox regression models in Study I, in which the dynamic confounders 
decreased the association between physical activity and diabetic nephropathy to a 
non-significant level, the finding regarding LTPA, its components and mortality was 
unaffected when adjusted for potential confounders. Also, the association between 
high LTPA frequency and incident CVD events, as well as between LTPA intensity 
and CVD mortality, were unaffected by the static and dynamic confounders in the 
final Cox regression model. There are many potential reasons for this. First, there 
are potential confounders, such as nutrition and socioeconomic status that were 
not assessed. Second, this might be due to reverse causality. Third, it is likely that 
multiple factors beyond the traditional CVD risk factors are involved in the potential 
causal pathway between the larger amount of physical activity and the decreased 
risk of CVD events and mortality. Factors such as inflammatory markers, insulin 
sensitivity, endothelial function and physical performance might be involved, but 
these were not included in our multivariable analyses.  
7.4 LTPA and the development of severe diabetic retinopathy 
A higher frequency of LTPA was associated with a lower incidence of severe diabetic 
retinopathy during follow-up. This finding was unaffected when adjusting for gender, 
renal function, age at onset and duration of diabetes, BMI, systolic blood pressure 
or triglycerides. However, after adjustment for HbA1c or history of smoking, the 
association was no more significant. The total amount or the other components 
of LTPA (intensity or duration of a single session) were not associated with severe 
diabetic retinopathy. 
Previous data on the subject are scarce, and physical activity has been associated 
with either a significant increase or a decrease in the risk of retinopathy development 
or its progression. Importantly, the earlier studies have shown no negative effect 
of physical activity on the development of severe diabetic retinopathy (299, 301, 
331). The WESDR showed that participation in high school team sports was 
associated with lower incidence of diabetic retinopathy, but only in a subgroup 
of women diagnosed with diabetes under the age of 14 (303). This association 
remained significant when adjusting for age and duration of diabetes. However, 
in men or in other individuals in the WESDR cohort, no associations were found. 
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Our finding extends these previous results to both genders and suggests that there 
is an association between LTPA and lower incidence of severe diabetic retinopathy.
In type 1 diabetes, glycaemic control, BP and triglycerides are treatable risk 
factors for diabetic retinopathy, as shown in randomised controlled trials (153, 
332–334). In addition, evidence suggests that obesity might also be a treatable risk 
factor for diabetic retinopathy (335). Physical activity potentially improves these risk 
factors. The association with frequent LTPA, however, was unaffected after adjusting 
for these dynamic confounders, suggesting that a potential beneficial effect may be 
mediated through other factors. These factors could include, for example, vascular 
endothelial function, insulin sensitivity and inflammation. In our multivariable 
analysis, the adjustment for HbA1c 
decreased the association with frequent physical 
activity to a non-significant level. This might be due to a beneficial effect of physical 
activity on glycaemia. Physical activity has been shown to improve insulin sensitivity 
in type 1 diabetes, although the benefit regarding HbA1c lowering has not been 
established (11, 276). On the other hand, HbA1c may not be an ideal marker of 
glycaemic control since it does not reflect the glycaemic variability.
Since diabetic retinopathy and diabetic nephropathy are closely associated, we 
expected that the intensity of LTPA would have been associated with the development 
of diabetic retinopathy as well since it was found to be associated with the progression 
of kidney disease. Also, our previous cross-sectional data showed that the intensity 
was associated with diabetic retinopathy (300). In this longitudinal data set, the 
incidence of severe diabetic retinopathy was even higher in the higher intensity 
groups, although not significant. The current ADA recommendations for diabetes 
and physical activity state that “vigorous aerobic or resistance exercise; jumping, 
jarring, head-down activities; and breath holding should be avoided in anyone 
with severe non-proliferative and unstable proliferative diabetic retinopathy” (268). 
Our observation suggests that these recommendations are well grounded. Further, 
our finding regarding the potential benefit of frequent physical activity is in line 
with the current ADA recommendations for physical activity in individuals with 
type 1 diabetes. However, our rather crude dichotomous classification of severe 
diabetic retinopathy (yes/no) and subjective measurement of LTPA may reduce 
our possibility to demonstrate possible associations with the other components 
of LTPA and identify potential drawbacks or benefits between intensive physical 
activity and diabetic retinopathy. For example, the EDTRS scale, as well as the 
thorough characterisation of the retinal status by optical coherence tomography 
(OCT), could possibly help identify individuals that might benefit and those that 
might be at risk of further damage by intensive physical activity.
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7.5 Methodology – strengths and limitations 
7.5.1 Study design and patients  
The study population in this thesis includes a cohort of individuals with type 1 
diabetes participating in the ongoing nationwide and multi-centre FinnDiane 
Study. The FinnDiane Study population is comprehensively characterised by 
medical history, clinical characteristics and presence of diabetic complications. The 
participation rate in the FinnDiane Study is high (336), and another strength of this 
thesis is a long follow-up period. Notably, the FinnDiane Study includes more than 
10% of the adult Finns with type 1 diabetes, and although it is not by definition a 
population-based study, the geographical distribution of the study population closely 
follows that of the general habituation in Finland. The risk of sample selection 
bias is reduced by recruiting individuals with type 1 diabetes from all levels of the 
Finnish healthcare system regardless of pre-existing diabetic complications. The 
study design is prospective and observational, and each study assessed different 
clinical outcomes: therefore, the cohorts in the sub-studies differ in sample size. 
However, all individuals with available relevant data were included.   
A main strength is the large size of the study cohort of individuals with type 1 
diabetes, suggesting that the findings can be considered plausible, valid and clinically 
important. Furthermore, the longitudinal observations from this thesis address 
obvious knowledge gaps and the limited amount of pre-existing data on physical 
activity and diabetic complications in individuals with type 1 diabetes. 
Regarding the hierarchy of evidence, a randomised controlled trial (RCT) – 
considered the gold standard – would provide the strongest level of evidence when 
measuring the cause-effect relationship of an exposure and an outcome (337, 
338). However, a randomised physical activity intervention study assessing the 
development of diabetic complications and mortality in individuals with type 1 
diabetes would be expensive, time-consuming and a relatively inefficient means 
to assess these outcomes due to their delayed manifestation and the need for a 
large study cohort. Therefore, observational studies are clinically important for 
addressing issues that are challenging or that are not addressable through RCTs 
(337, 339). However, it is important to carefully assess potential sources of biases 
while conducting observational research, as the risk is higher than in RCTs. Also, 
the role of potential biases must be considered when interpreting the results of 
observational studies. The risk for bias can be reduced by careful study design but 
can never be completely eliminated (338). On the other hand, RCTs have potential 
biases of their own, including selection biases (340). In addition, it is impossible 
to conduct a double-blinded RCT when assessing the effect of a physical activity 
intervention (337, 338).
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Although the FinnDiane Study design aims to reduce selection biases, it could 
not be totally avoided in our assessment of LTPA. The LTPA questionnaire was 
introduced in 2000 – not in 1997, when the FinnDiane Study was launched – and 
not all individuals with type 1 diabetes have answered the questionnaire after its 
introduction. First, the questionnaire is time-consuming to complete thoroughly, as 
reflected in the amount of information missing in the last section of the questionnaire 
(work-related physical activity). Second, it is possible that active individuals have 
completed the questionnaire and answered it more thoroughly than the sedentary 
individuals. 
Ruling out possible confounding factors is a constant challenge in observational 
studies (338, 341). The basic principle is that a confounder might either overestimate 
or suggest an association. On the other hand, it might also mask or underestimate 
a true association. The magnitude and direction of the bias is governed by the 
associations that the confounders have with the exposure and outcome. (341) In 
our study, we did address many, albeit not all, potential confounders by conducting 
Cox regression analyses. For example, nutrition and socioeconomic status were not 
evaluated by our study. However, we did use smoking as a confounder, and it has 
been shown to be strongly correlated with socioeconomic status (342). Additionally, 
we adjusted for many other potential confounders (blood pressure, BMI, lipids, 
glycaemic control) that are also risk factors for diabetic complications. On the 
other hand, studies have shown that these covariates themselves are influenced 
by physical activity (7). In other words, these risk factors might be intermediate 
variables and may be part of a potential causal pathway between physical activity 
and diabetic complications (Figure 8, B). Therefore, it would actually be expected 
that adjustment for these “dynamic” confounders would at least partially blunt the 
association of physical activity, mortality and diabetic complications. Indeed, this 
effect was seen in many of our multivariable analyses. The role of a confounding 
and an intermediate variable is illustrated in Figure 8. It is of note that a variable 
might simultaneously act as a confounder and as an intermediate variable (343).
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Figure 8. A) A confounder and B) an intermediate variable. Modified from Wakkee et al., 
“Multivariable Analysis”, Journal of Investigative Dermatology (2014) and MacKinnon et al., 
“Equivalence of the Mediation, Confounding and Suppression Effect”, Prevention Science (2000) 
(343, 344).
On the other hand, it is not always clear whether the outcome also impacts the 
exposure, i.e. “the chicken or egg dilemma” (345, 346). Therefore, the role of 
reverse causality is important to consider when evaluating our observed associations 
between low levels of physical activity, the development of diabetic complications 
and premature mortality. Importantly, the presence of diabetic complications at 
baseline might affect an individual’s ability to be physically active. This issue is 
partly addressed when assessing outcomes in a sub-group of individuals without 
albuminuria since these individuals are complication-free. However, there is always 
the possibility that more active individuals or those that perform a higher intensity 
of physical activity have different beneficial genetic, biological, psychological and 
social attributes – and the same attributes might also protect this group of individuals 
from premature death and diabetic complications (346, 347). Irrespective of how 
important RCTs are for the detection of causalities, the interpretation of the results 
requires further knowledge derived from observational prospective studies. 
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7.5.2 Assessment of LTPA 
LTPA was assessed using a subjective method. Objective measurement of physical 
activity is more precise but not applicable to large nationwide cohorts. On the other 
hand, objective measurements also have their own potential bias such as increased 
activity during surveillance. In this study, LTPA was self-reported and recalled from 
the past 12 months, increasing the risk of information bias. Participants might have 
over- or underestimated their amount and intensity of physical activity, leading to the 
misclassification of the total LTPA and the variables. Nevertheless, validation studies 
have shown that, within a cohort, questionnaires are able to classify individuals in 
rank order according to activity level (348, 349). In addition, the data on work-
related physical activity was limited and therefore not assessed, leading to a potential 
underestimation of the total amount of physical activity. Also, we did not assess 
the potential changes in LTPA since it was only assessed at baseline. However, 
based on behavioural studies, it is unlikely that sedentary individuals would become 
highly active (350). If anything, a possible change in physical activity habits during 
follow-up might have diluted our results. 
Another major strength of this study is that the KIHD LTPA questionnaire 
has previously been validated in the Finnish population and is custom-made for 
Finnish conditions. The reliability of the questionnaire has been assessed, and the 
studies have shown that the questionnaire is representative: the 12-month LTPA 
correlated with the maximum oxygen uptake with a regression coefficient between 
the total energy expenditure and the maximal oxygen uptake of 0.23 (351). Further, 
the questionnaire has been shown to be repeatable and to have a relatively small 
intraindividual variability (intraclass correlation coefficient 0.58) (308). Another 
strength is that we assessed not only the total amount of LTPA but also its different 
components. However, in the present study, the general intensity of physical activity 
was assessed by a subjective evaluation from the first part of the questionnaire 
(degree of shortness of breath and sweating). In future studies, however, we should 
also aim to use a more detailed and validated evaluation of intensity such as the 
Borg Scale (352). 
7.5.3 Assessment of clinical outcomes: the development of diabetic 
complications and death
So far, the FinnDiane Study has mainly focused on diabetic kidney complications. 
Therefore, the assessment of kidney status in particular (for example, albuminuria) 
has been carefully conducted. All medical files and laboratory values have been 
screened for the assessment of the albuminuria status using the two-out-of-three 
principles for the classification. Further, registries were used to identify all new 
initiations of dialysis treatment and transplantations in Finland. Thereafter, these 
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findings were verified from medical files. If signs of non-diabetic kidney disease were 
detected at any stage of the assessment, the patient was excluded from the analysis. 
For the assessment of the other micro- and macrovascular complications, another 
approach was taken. As a major strength of the thesis, we used nationwide registries 
(the Care Register for Health Care and the Finnish Causes of Death Registry) to 
identify these disease outcomes. The registries have been shown to have good 
coverage and validity (353). Due to the use of these nationwide registries, Studies 
II–IV lost no individuals to follow-up. Data on mortality were obtained and verified 
from the Finnish National Death Registry and the centre databases. All deaths were 
confirmed with death certificate data. The Care Register for Health Care, which was 
used to identify the CVD events (Study II), has been found to be appropriate for this 
purpose (353). Also, the information on severe diabetic retinopathy (laser treatment) 
was obtained from the hospital discharge registry, resulting in complete follow-up 
data. However, a review of fundus photographs would have certainly given a more 
precise assessment of the disease status, and this limitation might have resulted in 
potential disease misclassification both at baseline and at follow-up. However, if 
anything, this crude classification may have only diluted the findings in Study IV. 
7.6 Future directions
In this thesis, we were able to demonstrate several important and novel findings 
regarding the associations between physical activity, complications and mortality in 
type 1 diabetes. However, the findings are observational, and therefore, we cannot 
show direct causality. An ideal study design would be an RCT with hard endpoints; 
however, as discussed before, this approach involves feasibility issues. Also, the RCTs 
regarding potential risk factors are scarce, and they have been small and with short 
duration. Therefore, in the future, it would be important to conduct a well-planned 
RCT assessing the effect of physical activity on multiple clinical markers and risk 
factors with the simultaneous control of possible confounders such as nutrition, 
lifestyle factors and socioeconomic status. 
There is a clear need to enlighten the mechanisms of how physical activity 
benefits the individual with type 1 diabetes and to further establish what benefits 
the individual the most regarding intensity, duration and type of physical activity. 
Importantly, the future challenge is to get individuals with type 1 diabetes to be 
physically active. Physical activity guidelines applied to type 1 diabetes are mostly 
based on information gained from studies regarding the general population or 
individuals with type 2 diabetes. Therefore, clinicians need evidence-based 
instructions on how to prescribe physical activity to these individuals in order to 
improve the adherence to physical activity programs. 
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We assessed LTPA with a validated questionnaire, albeit subjectively. In the 
future, it is important to continue using well-validated tools and possibly to combine 
subjective and objective tools to assess physical activity. Technology rapidly develops 
and an intriguing method would be the use of available smart phone applications 
and data to assess physical activity levels. A combination of this data with a validated 
questionnaire might enable a more feasible intervention study with a larger study 
population to also evaluate hard endpoints. 
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8 SUMMARY AND CONCLUSIONS
I  Physical activity, particularly the intensity of LTPA, was associated with the 
development and progression of diabetic nephropathy in type 1 diabetes during 
a 6-year follow-up. This was significant after adjusting for “static” confounders 
such as duration of diabetes, gender and history of smoking. In contrast, 
“dynamic” confounding factors (HbA1c, BP, triacylglycerol and BMI), which could 
potentially be influenced by LTPA, incrementally decreased this association to 
a non-significant level. Also, the frequency of LTPA was associated with renal 
progression. This association decreased to a non-significant level after adjustment 
for either the static or dynamic confounders. The total amount or duration of 
LTPA was not associated with the progression of diabetic nephropathy. We 
separately analsyed the development of de novo microalbuminuria. LTPA 
intensity was associated with the development of microalbuminuria in a 
univariable model. 
II  We investigated the relationship of LTPA and the development of a first-ever 
CVD event during a 10-year follow-up. Higher LTPA, particularly its frequency 
and intensity, was associated with a decreased risk of incident CVD events 
in individuals with type 1 diabetes. LTPA frequency was also associated with 
incident CVD events in the final multivariable model after adjusting for many 
confounders (duration of diabetes, age at onset of diabetes, diabetic nephropathy, 
gender, triacylglycerol, BMI, SBP, HbA1c and smoking). We also separately 
analysed the relationship between physical activity and recurrence-free time 
from the baseline visit in a small group of individuals with a previous CVD event at 
baseline (n=106). Only the intensity of LTPA was associated with the recurrence-
free time after a major CVD event at baseline, even after the adjustment of 
gender, diabetic nephropathy, age at onset of diabetes and duration of diabetes. 
III  During an average follow-up of 11 years, LTPA and all its components (intensity, 
duration and frequency) were associated with all-cause mortality even after 
adjustment for the potential confounders of gender, diabetic nephropathy, 
duration of diabetes, age at onset of diabetes, SBP, triglycerides, BMI and HbA1c 
in a study population of 2639 individuals with type 1 diabetes. The intensity of 
LTPA was associated with CVD mortality after adjusting for all the previous 
confounders. We separately analysed the relationship between LTPA and all-
cause mortality in individuals with CKD and type 1 diabetes (n=310). Of the 
individuals with CKD, 41% died during follow-up. A higher total and frequency 
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of LTPA were independently associated with a lower risk of all-cause mortality 
when adjusted for the previous covariates.
IV  Our prospective findings show that physical activity, particularly a higher 
frequency of LTPA, was associated with a lower incidence of severe diabetic 
retinopathy in type 1 diabetes during follow-up. The finding was unaffected when 
adjusting for the potential confounders of gender, renal function, age at onset 
and duration of diabetes, BMI, SBP or triglycerides. However, after adjusting for 
HbA1c or history of smoking, the association was no more significant. The total 
amount of LTPA or its other components (intensity or the duration of a single 
session) were not associated with severe diabetic retinopathy during follow-up. 
General conclusions: The results of this thesis further establish that physical 
activity is beneficial for individuals with type 1 diabetes and should be an important 
part of their treatment regimen. In addition, physical activity also seems to benefit 
those with diabetic complications – notably diabetic nephropathy – and appears to 
be safe. Therefore, physical activity should also be advocated to these individuals. 
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APPENDIX
Physicians and nurses at health care centres participating in the collection of 
FinnDiane patients. 
FinnDiane Study Centres Physicians and nurses
Anjalankoski Health Centre S. Koivula, T. Uggeldahl
Central Finland Central Hospital, 
Jyväskylä
T. Forslund, A. Halonen, A. Koistinen,  
P. Koskiaho, M. Laukkanen, J. Saltevo,  
M. Tiihonen
Central Hospital of Åland Islands, 
Mariehamn
M. Forsen, H. Granlund, A-C. Jonsson,  
B. Nyroos
Central Hospital of Kanta-Häme, 
Hämeenlinna
P. Kinnunen, A. Orvola, T. Salonen,  
A. Vähänen
Central Hospital of Länsi-Pohja, 
Kemi
H. Laukkanen, P. Nyländen, A. Sademies
Central Ostrobothnian Hospital 
District, Kokkola
S. Anderson, B. Asplund, U. Byskata,  
P. Liedes, M. Kuusela, T. Virkkala
City of Espoo Health Centre
Espoonlahti A. Nikkola, E. Ritola
Tapiola M. Niska, H. Saarinen
Samaria E. Oukko-Ruponen, T. Virtanen
Viherlaakso A. Lyytinen
City of Helsinki Health Centre
Puistola H. Kari, T. Simonen
Suutarila A. Kaprio, J. Kärkkäinen, B. Rantaeskola
Töölö P. Kääriäinen, J. Haaga, A-L. Pietiläinen
City of Hyvinkää Health Centre S. Klemetti, T. Nyandoto, E. Rontu,  
S. Satuli-Autere
City of Vantaa Health Centre
Korso R. Toivonen, H. Virtanen
Länsimäki R. Ahonen, M. Ivaska-Suomela, A. Jauhiainen
Martinlaakso M. Laine, T. Pellonpää, R. Puranen
Myyrmäki A. Airas, J. Laakso, K. Rautavaara
Rekola M. Erola, E. Jatkola
Tikkurila R. Lönnblad, A. Malm, J. Mäkelä, E. Rautamo
Heinola Health Centre P. Hentunen, J. Lagerstam
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FinnDiane Study Centres Physicians and nurses
Helsinki University Central Hospital, 
Department of Medicine, Division of 
Nephrology
A. Ahola, J. Fagerudd, M. Feodoroff,  
D. Gordin, O. Heikkilä, K. Hietala,  
M. Korolainen, J. Kytö, S. Lindh,  
K. Pettersson-Fernholm, M. Rosengård-
Bärlund, M. Rönnback, A. Sandelin,  
A-R. Salonen, L. Salovaara, M. Saraheimo,  
JR Simonsen, L. Thorn, J. Tuomikangas,  
T. Vesisenaho, J. Wadèn
Herttoniemi Hospital, Helsinki V. Sipilä
Hospital of Lounais-Häme, Forssa T. Kalliomäki, J. Koskelainen, R. Nikkanen, 
N. Savolainen, H. Sulonen, E. Valtonen
Iisalmi Hospital E. Toivanen
Jokilaakso Hospital, Jämsä A. Parta, I. Pirttiniemi
Jorvi Hospital, Helsinki University 
Central Hospital
S. Aranko, S. Ervasti, R. Kauppinen-Mäkelin, 
A. Kuusisto, T. Leppälä, K. Nikkilä,  
L. Pekkonen
Jyväskylä Health Centre, Kyllö K. Nuorva, M. Tiihonen
Kainuu Central Hospital, Kajaani S. Jokelainen, P. Kemppainen,  
A-M. Mankinen, M. Sankari
Kerava Health Centre H. Stuckey, P. Suominen
Kirkkonummi Health Centre A. Lappalainen, M. Liimatainen,  
J. Santaholma
Kivelä Hospital, Helsinki A. Aimolahti, E. Huovinen
Koskela Hospital, Helsinki V. Ilkka, M. Lehtimäki
Kotka Heath Centre E. Pälikkö-Kontinen, A. Vanhanen
Kouvola Health Centre E. Koskinen, T. Siitonen
Kuopio University Hospital E. Huttunen, R. Ikäheimo, P. Karhapää,  
P. Kekäläinen, M. Laakso, T. Lakka,  
E. Lampainen, L. Moilanen, L. Niskanen,  
U. Tuovinen, I. Vauhkonen, E. Voutilainen
Kuusamo Health Centre T. Kääriäinen, E. Isopoussu
Kuusankoski Hospital E. Kilkki, I. Koskinen, L. Riihelä
Laakso Hospital, Helsinki T. Meriläinen, P. Poukka, R. Savolainen,  
N. Uhlenius
Lahti City Hospital A. Mäkelä, M. Tanner
Lapland Central Hospital, Rovaniemi L. Hyvärinen, S. Severinkangas, T. Tulokas
Lappeenranta Health Centre P. Linkola, I. Pulli
Lohja Hospital T. Granlund, M. Saari, T. Salonen
Loimaa Health Centre A. Mäkelä, P. Eloranta
Länsi-Uusimaa Hospital, 
Tammisaari
I-M. Jousmaa, J. Rinne
Malmi Hospital, Helsinki H. Lanki, S. Moilanen, M. Tilly-Kiesi
Mikkeli Central Hospital A. Gynther, R. Manninen, P. Nironen,  
M. Salminen, T. Vänttinen
Mänttä Regional Hospital I. Pirttiniemi, A-M. Hänninen
North Karelian Hospital, Joensuu U-M. Henttula, P. Kekäläinen, M. Pietarinen, 
A. Rissanen, M. Voutilainen
Nurmijärvi Health Centre A. Burgos, K. Urtamo
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FinnDiane Study Centres Physicians and nurses
Oulankangas Hospital, Oulainen E. Jokelainen, P-L. Jylkkä, E. Kaarlela,  
J. Vuolaspuro
Oulu Health Centre L. Hiltunen, R. Häkkinen, S. Keinänen-
Kiukaanniemi
Oulu University Hospital R. Ikäheimo
Päijät-Häme Central Hospital H. Haapamäki, A. Helanterä, S. Hämäläinen, 
V. Ilvesmäki, H. Miettinen
Palokka Health Centre P. Sopanen, L. Welling
Pieksämäki Hospital V. Javtsenko, M. Tamminen
Pietarsaari Hospital M-L. Holmbäck, B. Isomaa, L. Sarelin
Pori City Hospital P. Ahonen, P. Merensalo, K. Sävelä
Porvoo Hospital M. Kallio, B. Rask, S. Rämö
Raahe Hospital A. Holma, M. Honkala, A. Tuomivaara,  
R. Vainionpää
Rauma Hospital K. Laine, K. Saarinen, T. Salminen
Riihimäki Hospital P. Aalto, E. Immonen, L. Juurinen
Salo Hospital A. Alanko, J. Lapinleimu, P. Rautio,  
M. Virtanen
Satakunta Central Hospital, Pori M. Asola, M. Juhola, P. Kunelius, M-L. 
Lahdenmäki, P. Pääkkönen, M. Rautavirta
Savonlinna Central Hospital E. Korpi-Hyövälti, T. Latvala, E. Leijala
South Karelia Central Hospital, 
Lappeenranta
T. Ensala, E. Hussi, R. Härkönen, U. Nyholm, 
J. Toivanen
Tampere Health Centre A. Vaden, P. Alarotu, E. Kujansuu, 
H. Kirkkopelto-Jokinen, M. Helin, S. 
Gummerus, L. Calonius, T. Niskanen, T. 
Kaitala, T. Vatanen
Tampere University Hospital I. Ala-Houhala, T. Kuningas, P. Lampinen,  
M. Määttä, H. Oksala, T. Oksanen,  
K. Salonen, H. Tauriainen, S. Tulokas
Tiirismaa Health Centre, Hollola T. Kivelä, L. Petlin, L. Savolainen
Turku Health Centre I. Hämäläinen, H. Virtamo, M. Vähätalo
Turku University Central Hospital K. Breitholz, R. Eskola, K. Metsärinne,  
U. Pietilä, P. Saarinen, R. Tuominen,  
S. Äyräpää
Vaajakoski Health Centre K. Mäkinen, P. Sopanen
Valkeakoski Regional Hospital S. Ojanen, E. Valtonen, H. Ylönen, M. 
Rautiainen, T. Immonen
Vammala Regional Hospital I. Isomäki, R. Kroneld, M. Tapiolinna-Mäkelä
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